APD334  Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06 27 March 2017  
Clinical Trial Protocol : APD334 -003 
Study Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 
Parallel Group, Multi-Center Study to Investigate the Safety and 
Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative Colitis 
Study Number: APD334-003 
Study Phase: 2 
Product Name: APD334 
IND Number: 125,154 
EudraCT Number: 2015-001942‐28 
Indication: Ulcerative Colitis 
Investigators: Multicenter 
Sponsor: Arena Pharmaceuticals, Inc. 
6154 Nancy Ridge Drive 
San Diego, California  92121 
Date 
Original Protocol: 08 April 2015 
Amendment 01: 01 May 2015 
Amendment 02: 17 June 2015 
Amendment 03: 30 June 2015 
Amendment 04: 21 September 2015 
Amendment 05: 10 October 2016 
Amendment 06: 27 March 2017 
Confidentiality Statement  
This document contains confidential information of Arena Pharmaceuticals, Inc.  Unauthorized 
distribution, copying, or disclosure is strictly prohibited unless required by applicable law.  Persons 
receiving this information must be notified that it is confidential and may not be further disclosed.   Study ID: [REMOVED]
This NCT number has been applied to the document for 
purposes of posting on clinicaltrials.gov
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 2 of 101 PROTOCOL AMENDMENT S UMMARY  
The following is a list of major changes made to the APD334 -003 Protocol Amendment 05 
dated 10 October 2016 . Minor clarifications and corrections have been made throughout for 
consistency. These changes are incorporated in Protocol Amendment 06 dated 27 March 
2017.  
Section(s) Amended Description of Changes Made 
Header/Footer, Title Page, and 
TOC  Added “Amendment 06”, updated date to reflect finalization 
of amended protocol, updated pagination and TOC.  
Protocol Amendment Summary Updated table to include summary of changes to the protocol. 
Synopsis Updated sponsor contact details 
Synopsis Changed Primary Objective “ The primary objective will be to 
determine the effect of treatment with APD334 in inducing 
clinical remission at 12 weeks ” to: 
 
Current  “The primary objective of this proof-of-concept study 
is to determine the effect of treatment with APD334 in 
improving 3-component Mayo Clinic Score (score ranging 
from 0 to 9, including stool frequency, rectal bleeding and findings on endoscopy) at Week 12 ” 
Synopsis Added the following Secondary Objectives:  
• To determine the effect of treatment with APD334 on a 
combination of clinical remission and clinical response 
reflected by a composite endpoint at 12 weeks 
• To determine the effect of treatment with APD334 in 
inducing clinical remission at 12 weeks 
 
Synopsis Added the following Exploratory Objectives:  
 
• to determine the effect of APD334 treatment on Total 
Mayo Clinic Score at 12 weeks. 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 3 of 101 Synopsis Study Design: 
Changed the study description: “phase 2, dose -ranging, 
placebo- controlled clinical study” to:  
 
Current “phase 2, proof-of-concept and dose-ranging, 
placebo-controlled clinical study ” 
 Changed patients with the option to enroll in an extension 
study APD334- 005: “responder patients” to:  
Current “all patients”  
Synopsis Changed Primary Efficacy Endpoints “ The proportion of 
patients achieving clinical remission [defined as individual 
subscores of the 3-component Mayo Clinic score as follows: 
an endoscopy score (using flexible proctosigmoidoscopy) of 0 
or 1, a rectal bleeding score of 0, and a stool frequency score 
of 0 or 1 with a decrease of ≥ 1 point from baseline subscore at 
Week 12 ” to: 
 
Current  “ 
• The improvement of 3-component Mayo Clinic Score 
(score ranging from 0 to 9, including stool frequency, rectal 
bleeding and findings on endoscopy) at Week 12. ” 
Synopsis Added the following Secondary Efficacy Endpoints:  
 • The trichotomous composite endpoint of clinical remission 
and clinical response (score ranging 0 to 2: score 2 for 
achieving both clinical remission and clinical response; 1 for 
achieving only clinical response, and 0 for achieving neither) 
at Week 12 
• The proportion of patients achieving clinical remission 
[defined as individual subscores of the 3-component Mayo 
Clinic score as follows: an endoscopy score (using flexible 
proctosigmoidoscopy) of 0 or 1, a rectal bleeding score of 0, 
and a stool frequency score of 0 or 1 with a decrease of ≥ 1 
point from baseline subscore at Week 12 
Synopsis Added the following Exploratory Objectives:  
 
• Improvement in Total Mayo Clinic Score (score ranging 
from 0 to 12, including stool frequency, rectal bleeding and 
findings on endoscopy, and physician’s global assessment) at 
Week 12 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 4 of 101 Synopsis Data Analysis section updated to reflect new primary, 
secondary and exploratory Endpoints. 
Study Definition Added “Trichotomous composite endpoint” definition 
2. Study Objectives Updated Primary and Secondary Objectives according to 
changes highlighted in the Synopsis.  
3.1 Overall Study Design and 
Plan Study Design: 
Changed the study description: “phase 2, dose-ranging, 
placebo- controlled clinical study” to:  
Current “phase 2, proof-of-concept and dose-ranging, 
placebo-controlled clinical study ” 
 
Changed patients with the option to enroll in an extension 
study APD334- 005: “responder patients” to:  
Current “all patients (responders and non- responders)”  

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 5 of 101 4.2 Inclusion Criteria 
4.3 Exclusion Criteria 
6.12.1 Permitted Medications for 
the Treatment of UC Changed “ for the 4 weeks immediately prior to screening ” to: 
 
Current  “for the 4 weeks immediately prior to screening  
endoscopy assessment ” 
6.15 Study and Site 
Discontinuation Added section 6.15 to provide reasons to terminate the study 
or replace a site. 
9 Planned Statistical Methods Added specifications related to the intention of Section  9. 
9.1.1 Hypotheses and Objectives Primary, Secondary and Exploratory Objectives and 
Hypothesis were updated to reflect the updated Primary, 
Secondary and Exploratory Endpoints. 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 6 of 101 9.5 Efficacy Endpoints Primary, Secondary and Exploratory Efficacy Endpoints were 
updated reflecting the changes highlighted in the Synopsis 
amendment summary section. 
9.6.1 Primary, Secondary and 
Exploratory Efficacy Analysis Primary, Secondary and Exploratory Efficacy Analysis were 
updated reflecting the changes highlighted in the Primary, 
Secondary and Exploratory Endpoints section. 
9.6.3 Multiplicity Updated to reflect the new Primary, Secondary and 
Exploratory Endpoints. 
 
Removal of Figure 1 – Statistical testing procedure in the UC 
Trial  
9.6.4 Interim Analysis Changed “No interim analyses are planned for this study”, to:  
 
Current  “Sponsor may plan an unblinded interim analysis at 
time when sufficient number of patients have finished 12 
weeks of treatment. If Sponsor decides to perform an interim 
analysis, it will be operated by an independent Data Review 
Committee (DMC).  The revision of statistical analysis plan 
(SAP) with detailed interim analysis specifications and a DMC 
charter will be provided to regulatory agency in timely manner and will be finalized prior to the interim analysis. ” 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 7 of 101 TABLE OF CONTENTS  
PROTOCOL AMENDMENT S UMMARY  ................................ ................................ .............. 2 
TABLE OF CONTENTS  ................................ ................................ ................................ ........... 7 
SYNOPSIS  ................................ ................................ ................................ ............................... 12 
LIST OF ABBREVIATION S ................................ ................................ ................................ ..20 
STUDY DEFINITIONS  ................................ ................................ ................................ .......... 23 
1 INTRODUCTION  ................................ ................................ ................................ ........... 25 
1.1 Background Information  ................................ ................................ ........................ 26 
1.1.1 Rationale for Proposed Clinical Study  ................................ ......................... 26 
1.1.2  Summary of Preclinical Data  ................................ ................................ .......26 
1.1.3  Summary of Clinical Data  ................................ ................................ ........... 27 
1.2 Ethics and Regulatory Considerations  ................................ ................................ ...29 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....31 
2.1 Primary Objective  ................................ ................................ ................................ ..31 
2.2 Secondary Objectives ................................ ................................ ............................. 31 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 32 
3.1 Overall Study Design and Plan  ................................ ................................ .............. 32 
3.2 Study Duration and Dates  ................................ ................................ ...................... 32 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ........... 36 
4.1 Study Population  ................................ ................................ ................................ ....36 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...36 
4.3 Exclusion Criteria  ................................ ................................ ................................ ..39 
5 STUD Y TREATMENT(S)  ................................ ................................ .............................. 42 
5.4 Test Article Accountability  ................................ ................................ .................... 42 
5.5 Investigational Product Retention at Study Site  ................................ .................... 42 
5.6 Dosage and Administration ................................ ................................ .................... 42 
5.7 Method of Assigning Patients to Treatment Groups ................................ .............. 43 
5.8 Randomization and Blinding  ................................ ................................ ................. 43 
5.8.1  Randomization  ................................ ................................ ............................. 43 
5.8.2  Blinding ................................ ................................ ................................ ........ 43 
5.8.3  Maintenance of Randomization Codes and Code -break Procedures  ........... 44 
5.9 Study Restrictions  ................................ ................................ ................................ ..44 
5.9.1  Fluid and Food Intake  ................................ ................................ .................. 44 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 8 of 101 5.10  Data Safety Monitoring Board  ................................ ................................ ............... 45 
6 STUDY PROCEDURES  ................................ ................................ ................................ .46 
6.1 Informed Consent ................................ ................................ ................................ ...46 
6.2 Medi cal and Social History  ................................ ................................ .................... 46 
6.2.1  Prior Therapies  ................................ ................................ ............................. 46 
6.2.2  History of UC  ................................ ................................ ............................... 46 
6.3 Physical and Neurological Examinations  ................................ .............................. 46 
6.3.1  Physical Examination ................................ ................................ ................... 46 
6.3.2  Neurological Examination  ................................ ................................ ........... 47 
6.4 Vital Signs  ................................ ................................ ................................ .............. 47 
6.6 Tuberculosis Screening and Chest X - ray ................................ .............................. 49 
  
6.8 Clinical Laboratory Tests  ................................ ................................ ....................... 50 
6.8.1  Laboratory Parameters  ................................ ................................ ................. 50 
6.8.2  Virology  ................................ ................................ ................................ .......50 
6.8.3  Drugs of Abuse Screen  ................................ ................................ ................ 51 
6.8.4  Urinalysis  ................................ ................................ ................................ .....51 
  
6.8.6  Sample Collection, Storage, and Shipping  ................................ .................. 51 
6.8.7  Blood Volume  ................................ ................................ .............................. 51 
6.9 Efficacy Assessments ................................ ................................ ............................. 51 
6.9.1 Flexible Proctosigmoidoscopy  ................................ ................................ .....51 
  
6.9.3  Stool Sample  ................................ ................................ ................................ 52 
  
  
6.9.6  Electronic Clinical Outcomes Assessments (eCOA)  ................................ ...52 
6.9.7  Complete Mayo Clinic Score, 3 -component Mayo Clinic Score, and 
 ................................ ................................ ......................... 53 
6.10  and Hematologic Assessments  ................................ ................... 54 
  
6.10.2  Hematologic Sampling ................................ ................................ ................. 54 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 9 of 101 6.10.3  Total Blood Volume  ................................ ................................ .................... 55 
6.11 Adverse Events Assessments  ................................ ................................ ................. 55 
6.11.1  Adverse Event Reporting  ................................ ................................ ............. 55 
6.11.1.1  Progressive Multifocal Leukoencephalopathy (PML) Checklist  .......56 
6.11.2  Serious Adverse Events and Expedited Reporting of Adverse Events  ........ 57 
6.11.2.1  Patie nt and Patient -partner Pregnancy  ................................ ............... 58 
6.11.3  Assessment of Adverse Event Severity  ................................ ....................... 58 
6.11.4  Assessment of Adverse Event Relationship to Study Medication  ............... 59 
6.11.5  Assessment of Adverse Event Outcome  ................................ ...................... 59 
6.11.6  Action Taken for Adverse Event  ................................ ................................ .59 
6.11.7  Action Taken for Study Drug  ................................ ................................ ......60 
6.11.8  Collection of Extra Laboratory Samples/Investigations  .............................. 60 
6.11.9  Follow -up of Adverse Events Present at Last Scheduled Study Visit  ......... 60 
6.12  Concomitant Medic ations and Procedures ................................ ............................. 60 
6.12.1  Permitted Medications for the Treatment of UC  ................................ ......... 61 
6.12.2  Excluded Medications  ................................ ................................ .................. 61 
6.13  Removal of Patients from the Trial or Study Drug  ................................ ................ 61 
6.13.1  Handling of Withdrawals  ................................ ................................ ............. 62 
6.13.2  Replacements  ................................ ................................ ............................... 62 
6.14  Allowable Visit and Procedure Windows  ................................ .............................. 62 
6.15  Study and Site Discontinuation  ................................ ................................ .............. 63 
7 STUDY ACTIVITIES  ................................ ................................ ................................ .....64 
  ................................ ................................ ............ 64 
7.2 Screening Failures  ................................ ................................ ................................ ..65 
7.2.1  Re-screening  ................................ ................................ ................................ 65 
7.3  Holter Fitting and Monitoring  ................................ ................................ ....66 
7.4 Treatment Period  ................................ ................................ ................................ ....66 
  ................................ ................................ ............ 66 
7.4.2  At-home Holter Removal  ................................ ................................ ............. 67 
  ................................ ................................ ..67 
  ................................ .......... 67 
 68 
8 DATA MANAGEMENT ................................ ................................ ................................ .69 
8.1 Data C ollection  ................................ ................................ ................................ ......69 
8.2 Data Coding  ................................ ................................ ................................ ........... 69 
8.2.1  Adverse Events  ................................ ................................ ............................ 69 
8.2.2  Concomitant Medications and Non -drug Treatments  ................................ ..69 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 10 of 101 8.2.3  Medical History  ................................ ................................ ........................... 69 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 70 
9.1 Hypotheses and Objectives  ................................ ................................ .................... 70 
9.1.1  Objectives  ................................ ................................ ................................ ....70 
9.1.1.1  Primary Objective  ................................ ................................ .............. 70 
9.1.1.2  Secondary Objective(s)  ................................ ................................ ......70 
9.1.1.3  Safety Objective  ................................ ................................ ................. 70 
9.1.1.4  Exploratory Objective(s)  ................................ ................................ ....70 
9.1.2  Hypotheses  ................................ ................................ ................................ ...71 
9.1.2.1  Prim ary Hypothesis  ................................ ................................ ............ 71 
9.1.2.2  Secondary Hypotheses  ................................ ................................ .......72 
9.2 Sample Size and Power Calculations  ................................ ................................ .....72 
9.3 Analysis Populations  ................................ ................................ .............................. 72 
9.4 Demographics and Baseline Characteristics  ................................ .......................... 73 
9.5 Efficacy Endpoints  ................................ ................................ ................................ .73 
9.6 Statistical Methods  ................................ ................................ ................................ .74 
9.6.1 Primary Efficacy Analysis  ................................ ................................ ........... 74 
9.6.1.1  Secondary and Exploratory Efficacy Analyses ................................ ..75 
9.6.2  Subgroup Analyses  ................................ ................................ ...................... 76 
9.6.3 Multiplicity  ................................ ................................ ................................ ..77 
9.6.4  Interim Analysis  ................................ ................................ ........................... 78 
9.6.5  Data Safety Monitoring Board  ................................ ................................ .....78 
  
9.8 Safety Analysis  ................................ ................................ ................................ ......78 
9.8.1  Adverse Events  ................................ ................................ ............................ 79 
9.8.2  Physical Examinations  ................................ ................................ ................. 79 
9.8.3  Concomitant Medication  ................................ ................................ .............. 79 
9.8.4  Vital Signs  ................................ ................................ ................................ ....79 
9.8.5  Clinical Laboratory Values  ................................ ................................ .......... 80 
  
10 REGULATORY REQUIREME NTS ................................ ................................ ............... 81 
10.1  Pre-Study Documentation  ................................ ................................ ...................... 81 
10.2  Investigator Obligations  ................................ ................................ ......................... 81 
10.3  Patient Confidentiality  ................................ ................................ ........................... 81 
10.4  Informed Consent ................................ ................................ ................................ ...81 
10.5  Institutional Review Board  ................................ ................................ .................... 82 
11 PROTOCOL MANAGEMENT AND ADMINISTRATIVE C ONSIDERATIONS  ......83 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 11 of 101 11.1  Study Documentation ................................ ................................ ............................. 83 
11.2  Protocol Interpretation and Compliance  ................................ ................................ 83 
11.3  Study Monitoring  ................................ ................................ ................................ ...83 
12 PRINCIPAL INVESTIGAT OR SIGNATURE PAGE  ................................ ................... 84 
13 REFERENCES  ................................ ................................ ................................ ................ 86 
PROTOCOL SIGNA TURE PAGE  ................................ ................................ ......................... 89 
 
LIST OF IN -TEXT TABL ES 
  
Table  2. Examples of eDiary Subscore Entries for Study Eligibility and 
Corresponding Subscore Derivation  ................................ ............................... 53 
 
LIST OF APPENDICES  
Appendix 1  Progressive Multifocal Leukoencephalopathy (PML) Checklist  ................... 90 
 
Appendix 3  Mayo Clinic Score – SAMPLE  ................................ ................................ ....101 
 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 12 of 101 SYNOPSIS  
Name of Drug: APD334 
Indication: Ulcerative Colitis 
Sponsor: Arena Pharmaceuticals, Inc. 
6154 Nancy Ridge Drive San Diego, California 92121 
Name of Sponsor 
Contact:  
 
Are
na Pharmaceuticals, Inc 
6154 Nancy Ridge Drive 
San Diego, California 92121 Phone  
 
 
Name of Principal 
Investigator(s): Multi-center 
Medical Monitor:  
 
Are
na Pharmaceuticals, Inc. 
Phone:  
Mobile:  
 
Test Product, Dose 
and Mode of Administration: • 1 mg APD334 once daily (q.d.) for 12 weeks  
• 2 mg APD334 once daily (q.d.) for 12 weeks  
• Placebo once daily (q.d.) x 12 weeks 
 
The route and mode of administration of APD334 and placebo capsules will be oral with an adequate amount of water (240 mL). 
Concurrent 
Control: Placebo; microcrystalline cellulose in hard gelatin capsules 
Objectives: Primary Objective: 
The primary objective of this proof-of-concept study is to 
determine the effect of treatment with APD334 in improving 3-
component Mayo Clinic Score (score ranging from 0 to 9, including stool frequency, rectal bleeding and findings on endoscopy) at Week 12  

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 13 of 101 Secondary Objectives: 
The secondary objectives of this study are: 
• To determine the effect of treatment with APD334 on a 
combination of clinical remission and clinical response reflected by a composite endpoint at 12 weeks 
• To determine the effect of treatment with APD334 in inducing clinical remission at 12 weeks 
• To determine the effect of treatment with APD334 in 
inducing clinical response at 12 weeks 
• To determine the effect of treatment with APD334 on endoscopic improvement at 12 weeks 
 Safety Objective: 
The safety objective of this study is to determine the safety 
profile and tolerability of APD334 induction treatment. 
 
 Exploratory Objectives: 
The exploratory objectives of the study are: 
• to determine the effect of APD334 treatment on Total 
Mayo Clinic Score at 12 weeks. 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 14 of 101 Study Design: This phase 2, proof- of-concept and dose-ranging, placebo-
controlled clinical study will test 2 doses of APD334 or placebo 
in up to 240 patients with moderately to severely active ulcerative colitis.  
 will be 
randomized into a double-blind, placebo-controlled study, receiving one of 2 doses of APD334 or matching placebo for 12 weeks.  
Treatment arms will consist of once daily (q.d.) doses of 1 mg 
APD334, 2 mg APD334, or matching placebo. Patients will be randomized in a 1:1:1 ratio and will be stratified by presence or absence of current oral corticosteroid usage and previous 
exposure to TNFα antagonists.  
Entry criteria will be based on confirmation of moderately to 
severely active UC, as defined by a 3-component Mayo Clinic 
 
 
 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 15 of 101 At the end of the study all patients will have the option to enroll 
in an extension of the study (APD334-005) following completion of all study procedures and providing they meet all inclusion criteria for the extension study.  
Patients who do not participate in the extension study (APD334-
005) will have a 2-week follow-up visit after the last clinical visit.  
Study Site(s): This study will be conducted in approximately 100 clinical 
centers worldwide. 
Patient Population:   
 
 
 
 
  
Duration per 
Patient: ~18 weeks: ~28 days of screening, followed by a 12-week 
induction period. Patients who do not participate in the 
APD334-005 extension study will have a 2-week follow-up visit after the last clinical visit. 
Clinic visits will occur during the screening period (to be 
completed up to ~28 days before first dose of study medication) 
and approximately every 2-4 weeks during the study. Additional visits may occur at the discretion of the investigator. 
Patient 
Assignment: Eligible patients will be randomized in a 1:1:1 ratio to receive 
once daily (q.d.) doses of 1 mg APD334, 2 mg APD334, or matching placebo. 
Sample Size:  Up to 240 patients total. 
Efficacy Endpoints Primary: 
• The improvement of 3-component Mayo Clinic Score 
(score ranging from 0 to 9, including stool frequency, rectal bleeding and findings on endoscopy) at Week 12.  
 Secondary: 
• The trichotomous composite endpoint of clinical 
remission and clinical response (score ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 for achieving only clinical response, and 0 
for achieving neither) at Week 12 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 16 of 101 • The proportion of patients achieving clinical remission 
[defined as individual subscores of the 3-component 
Mayo Clinic score as follows: an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, a rectal 
bleeding score of 0, and a stool frequency score of 0 or 1 with a decreas e of ≥ 1 point from baseline subscore at 
Week  12 
• The proportion of patients who achieve clinical response [defined as a decrease in the 3-component Mayo Clinic score of ≥ 2 points an d a decrease of ≥ 30% with either a 
decrease of rectal bleeding of ≥ 1 or rectal bleeding score 
of 0 or 1] at W eek 12 
• The proportion of patients who achieve endoscopic 
improvement [defined as Mayo endoscopic subscore 
(using findings of flexible proctosigmoidoscopy) of ≤ 1 
point] at Week 12 
 
Exploratory: 
• Improvement in Total Mayo Clinic Score (score ranging 
from 0 to 12, including stool frequency, rectal bleeding and findings on endoscopy, and physician’s global 
assessment) at Week 12 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 17 of 101 Safety 
Assessments: • Physical examinations including ophthalmoscopy (and 
optical coherence tomography [OCT], where available) 
• Clinical laboratory tests to include hematology, serum 
chemistry, coagulation, and urinalysis 
• Vital sign measurements 
• Pulmonary Function Tests (PFTs)  
• 12-lead electrocardiograms (ECGs) 
• Adverse event reporting 
 
  
 
  

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 18 of 101  
 
Data Analyses: The primary analysis will be based on the change of 3-
component Mayo Clinic Score at Week 12 from baseline using an analysis of covariate (ANCOVA) model with terms for treatment, current oral corticosteroid use, prior exposure to TNFα antagonists and baseline value as covariate.  Least -
squares mean (LSM) by treatment group and its 95% confidence 
interval (CI), and least-squares mean difference between 
treatment group and its 95% CI will be reported. 
The secondary analyses include following: 
• Trichotomous composite endpoint of clinical remission 
and clinical response at Week 12 is an ordinal categorical endpoint with 3 categories (2, 1, 0).  It will be analyzed using Cochran-Mantel-Haenszel method 
adjusted for the stratification factors of presence or absence of current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists .  The testing 
statistic will be computed using modified ridit score for 
between-treatment comparison.  
• The proportion of patients who achieve clinical 
remission, clinical response, or endoscopic improvement 
will be analyzed individually using Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors of presence or absence of current oral corticosteroid therapy at baseline and previous exposure to TNFα antagonists, to compare the difference of proportions between treatment group. The CMH stratified risk difference and its 95% confidence interval will be provided 
Mayo Clinic Score data handling: for each visit during the study 
(excluding the screening/baseline visit which uses 10 prior days), stool frequency and rectal bleeding subscores will be derived from electronic patient diaries completed over the 7 days prior to a study visit. Note that the day prior, day of and day after proctosigmoidoscopy will not be used for patient diary entry because of the required bowel prep for the procedure. These subscores will be calculated using the following rules: 
 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 19 of 101 1. The scores from the 3 most recent days prior to the 
actual day of the study visit will be averaged and rounded to the nearest integer. 
2. If patient diary entries from 3 days are not available, the 
scores from the 2 most recent entries will be averaged 
and rounded to the nearest integer. 
3. If less than 2 days of diary data are available, the subscore will be considered missing. 
All patients who prematurely discontinue for any reason will be considered failures (non-responders) for all the proportion based 
endpoints. 
Exploratory efficacy analyses: 
Dose response 
analyses will be performed using ANCOVA 
model for continuous variables, or logistic regression model for 
categorical variables, as appropriate.  Treatment group and appropriate baseline covariates will be included in the analysis 
model.  Statistical testing of dose response trend will be based 
on appropriate contrast statement assuming monotonic dose response profile in placebo, APD334 low dose and APD334 high dose.  
A statistical testing procedure will be constructed to manage 
multiplicity issues concerning primary and secondary efficacy 
analyses in order to control overall Type I error rate for efficacy testing not exceeding 0.05. The details of testing procedure will be specified in a separate Statistical Analysis Plan. 
For the comparison of the proportion of patients who achieve 
clinical remission between APD334 versus placebo, a sample of 
~80 patients per group will provide 80% power to detect a 
difference of 18% (from 10% to 28%) at α=5% (2 -sided test). 
This calculation is based upon an assumed placebo rate of 10%. 
Safety information after administration of multiple doses of 
APD334 in patients with moderately to severely active ulcerative colitis will be evaluated by tabulating adverse experiences and clinical assessment of clinical laboratory data. 
Date: 27 March 2017 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 20 of 101 LIST OF ABBREVIATION S 
µg microgram 
ABPM ambulatory blood pressure monitor 
ADL Activities of Daily Living 
ALB  albumin 
ALK -P alkaline phosphatase 
ALT  alanine aminotransferase (SGPT) 
ANOVA  analysis of variance 
AST aspartate aminotransferase (SGOT) 
bpm beats per minute 
BUN blood urea nitrogen 
Ca calcium 
CBC  complete blood count (test) 
CFR  Code of Federal Regulations 
CGMP Current Good Manufacturing Practice 
CI confidence interval 
CIA collagen-induced arthritis 
Cl chloride 
CL/F apparent oral clearance 
CLr renal clearance 
CRF  case report form 
CRO  contract research organization 
DSMB Data Safety Monitoring Board 
EAE experimental autoimmune encephalomyelitis 
ECG electrocardiogram 
eCRF electronic CRF 
ED50 median effective dose 
ELISA  enzyme-linked immunosorbent assay 
FDA Food and Drug Administration 
FEF 25-75% mean forced expiratory flow between 25 and to 75% of FVC 
FEV 1 forced expiratory volume in the first second 
FVC forced vital capacity 
GCP Good Clinical Practice 
GGT  gamma glutamyl transferase 
Hb hemoglobin 
HBsAg hepatitis B surface antigen 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 21 of 101 hCG human chorionic gonadotropin 
Hct hematocrit 
HCV hepatitis C virus 
HDPE High-density polyethylene 
HIV human immunodeficiency virus 
h hour 
HR heart rate 
  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee 
IND Investigational New Drug  
IRB Institutional Review Board 
INR International Normalized Ratio 
kg kilogram 
LDH  lactate dehydrogenase 
MCH mean corpuscular hemoglobin 
MCS Mayo Clinic score 
MCV mean corpuscular volume 
MedDRA Medical Dictionary for Regulatory Activities 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
  
MRSD maximum recommended starting dose 
Na sodium 
NOAEL no observed adverse effect level 
OCT optical coherence tomography 
OTC over-the-counter 
PA posteroanterior 
PD pharmacodynamic 
PBL peripheral blood lymphocyte 
PFT pulmonary function test 
PI Principal Investigator 
  
PML  progressive multifocal leukoencephalopathy 
PRO  patient reported outcome 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 22 of 101 PT prothrombin time  
PTT partial thromboplastin time 
RBC  red blood cell (count) 
RIBA  recombinant immunoblot assay 
S1P(1-5) sphingosine 1-phosphate (1-5) receptor 
SAE serious adverse event 
SAS statistical analysis software 
SBP systolic blood pressure 
SD standard deviation 
sec second 
SOP(s) standard operating procedure(s) 
TEM T effector memory cells 
VICF  Voluntary Informed Consent Form 
VS vital signs 
WBC  white blood cell (count) 
WHO World Health Organization  
WHODRUG World Health Organization Drug Dictionary 
 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 23 of 101 STUDY DEFINITIONS  
Term  Definition 
Mayo Clinic score (Complete 
Mayo or MCS) Instrument designed to measure disease activity of 
ulcerative colitis consisting of 4 subscores: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment with each component ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Total score therefore ranges from 0 to 12, with a higher score indicating more 
severe disease. 
3-component Mayo Clinic 
score Consists of 3 of the 4 subscores found in the complete 
Mayo Clinic score as follows: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy. Total score range: 0 to 9, each component ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). 
Physician’s global 
assessment The physician’s global assessment acknowledges the three 
other criteria findings of the Mayo Clinic score; the patient’s daily record of abdominal discom fort and general 
sense of well-being, and other observations, such as physical findings and the patient’s performance.  Total 
score range: 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). 
Clinical Response Decrease in the 3-component Mayo Clinic score of ≥ 2 
points and a decrease of ≥ 30% with either a decrease of 
rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 12.  
Clinical Remission Individual subscores of the 3-component Mayo Clinic 
score as follows: an endoscopy score (using flexible 
proctosigmoidoscopy) of 0 or 1, a rectal bleeding score of 0, and a stool frequency score of 0 or 1 with a decrease of ≥ 1 point from baseline at Week 12. 
Trichotomous composite 
endpoint An ordinal categorical endpoint with 3 scores: score 2 for 
achieving both clinical remission and clinical response, 1 for achieving only clinical response, 0 for achieving neither. 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 24 of 101 Term  Definition 
Endoscopic Improvement Mayo endoscopic subscore (using findings of flexible 
proctosigmoidoscopy) of ≤ 1 point at Week 12. 
Intolerable AE Adverse event leading to study drug discontinuation. 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 25 of 101 1 INTRODUCTION  
APD334 is an orally available, selective, sphingosine 1 -phosphate 1 receptor (S1P 1) agonist.  
The S1P 1 receptor is a physiological mediator which has been shown to regulate lymphocyte 
recirculation between lymphoid tissue and blood. Binding and internaliza tion of the S1P 1 
receptor may result in lymphocyte retention within lymphoid tissue, with subsequent 
reduction in peripheral lymphocyte count and lymphocyte availability for recruitment to sites 
of inflammation.  S1P 1 receptor surface expression is require d for S1P gradient -mediated 
lymphocyte migration out of lymphoid tissue into the circulation.1  
APD334 is being developed  to treat autoimmune diseases. Initial investigations will focus on  
Inflammatory Bowel Disease (IBD) , which is a broad term that describes condition s with 
chronic or recurring immune response and inflammation of the gastrointestinal tract .2 There 
are two major types of IBD: Crohn’s disease (CD) and  ulcerative colitis (UC) . These are 
chronic remittent or progressive inflammatory conditions that may affect the entire 
gastrointestinal tract (CD) and the colonic mucosa (UC), and are associated with an increased 
risk for colon cancer.11  Collectively, p atients with IBD suffer from a multitude of GI 
symptoms, including diarrhea, rectal bleeding and abdominal pain.  
The causes of these IBDs  are not completely understood, but 3 characteristics define their 
etiology: (1) genetic predisposition; (2) an altered, dysregulated immune response; and (3) an 
altered response to gut microorganisms.2 The triggering event for the activation of the 
immune response in IBD has yet to be identified, but possible factors related to this event 
include a pathogenic organism ( as yet unidentified) or an inappropriate response to a 
normally innocuous microbial or other antigen (perhaps due to failure to downgrade the 
inflammatory response, and/or to repeated exposure to such antigen from an alteration in 
barrier function).2  Once the inflammation has been triggered, it may be difficult for the IBD 
patient’s immune system to turn off the respons e.3 
The number of patients diagnosed with IBD has dramatically increased worldwide over the 
past 50 years.5 In 2014, The Crohn’s and Colitis Foundation of American estimated that 
approximately 1.6 million people are affected by IBD in the United States (US) alone6, with 
as many as 70,000 new cases diagnosed in the US each year7. In Europe, an estimated 2.5 – 3 
million people are affected by IBD8 and as many as 5 million may be affected worldwide9.  
Universally, incidence rates for both Crohn's disease and ulcerative colitis were highest 
among individuals between 20 and 40 years old. Thus, IBD affects individuals in the most 
healthy and productive years of life,  resulting in long -term cost to the patient, health -care 
system and society.10 
Treatment for patients  with IBD is generally for symptomatic care (relief of symptoms) and 
mucosal healing and includes 5 major classes of medications: aminosalicylates (5 -ASA), 
antibiotics, corticosteroids, immunomodulators, and biologic therapies. These drugs are 
generally pr escribed in a “step -up” approach, with escalation of the medical regimen until a 
response is achieved14.   
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 26 of 101  
 Lymphocyte trafficking agents such as 
natalizumab  and vedolizumab,  both injectable or infused therapies, have demonstrated proof -
of-concept in IBD indications.  And more recently, R CP1063, an S1P 1 oral receptor 
modulator showed promising results in a Phase 2 study for ulcerative colitis . The availability 
of oral lymphocyte trafficking agent s such as  APD334  would  offer patients a n additional,  
more convenient treatment for  IBD.  
1.1 Background Information  
1.1.1  Rationale for Proposed Clinical Study  
UC is characterized by diffuse mucosal inflammation limited to the colon which involves the 
rectum in about 95% of cases and may extend proximally in a symmetrical, circumferential, 
and uninterru pted pattern to involve parts or all of the large intestine.12 Symptoms for UC can 
vary, depending on the location and severity of inflammation, but some of the most common 
are diarrhea, abdominal cramps and rectal bleeding. The ha llmark clinical symptom is bloody 
diarrhea often with prominent symptoms of rectal urgency and tenesmus.12 
The S1P 1 receptor signaling on lymphocytes allows their exit from lymph nodes along a S1P 
gradient. Functional antagonism of these S1P 1 receptors results in retention of lymphocytes 
in lymph nodes and prevents their egress to the periphery.  It is th rough this mechanism that 
APD334 may potentially reduce inflammation in inflammatory bowel disease.  Lymphocyte 
lowering has been correlated with clinical efficacy for S1P functional antagonists in multiple 
sclerosis, psoriasis, and ulcerative colitis. Thi s same mechanism may also be useful in 
treating a variety of different inflammatory and autoimmune diseases.  
This study is designed to test the safety and efficacy  of APD334 as a means to reduce the 
inflammation in the GI tract and induce a clinical respon se or remission in patients with 
severely to moderately active ulcerative colitis.  
1.1.2  Summary of Preclinical Data  

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 27 of 101 1.1.3  Summary of Clinic al Data  

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 28 of 101 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 29 of 101 1.2 Ethics and Regulatory Considerations   
The study will be conducted in compliance with the  International Conference on 
Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP), Title 21 of the United 
States (US) Code of Federal Regulations (CFR) Part 50 (21CFR §50 (Protection of Human 
Subjects), 21 CFR §56 (Institutional Review Boards [I RB]), and 21 CFR §312 
(Investigational New Drug [IND])  and applicable regulatory requirements , the study 
protocol, and where applicable, sponsor and / or Contract Research Organization (CRO) 
Standard Operating Procedures ( SOPs ). The protocol and informed c onsent will be submitted 
for consideration by the appropriate IRB /IEC  and written approval from the Chair or 
designated deputy of the IRB /IEC  is required before clinical activities of the study can 
commence.  
The IRB /IEC  must be notified promptly by the investigator of the following:  
• Deviations from, or changes in, the protocol to eliminate immediate hazards to the trial 
volunteers  
• Changes increasing the risk to volunteers and/or affecting significantly the conduct of 
the trial 
• All AEs that meet the definition of a SAE  
• New information that may adversely affect the safety of the volunteers or the conduct of 
the trial  
 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 30 of 101 Any changes to the protocol will be made by means of a form al written protocol amendment. 
All amendments wi ll require IRB /IEC  approval before implementation except when changes 
to the protocol are required immediately to eliminate hazards to the volunteer.  
 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 31 of 101 2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary objective of this proof -of-concept study will be to deter mine the effect of 
treatment with APD334 in improving 3 -component Mayo Clinic score (score ranging from 0 
to 9, including stool frequency, rectal bleeding and findings on endoscopy) at 12 weeks . 
2.2 Secondary Objectives  
The secondary objectives of th e study a re: 
• To determine the effect of treatment with APD334 on a combination of clinical 
remission and clinical response reflected by a composite endpoint at 12 weeks  
• To determine the effect of treatment with APD334 in inducing clinical remission at 
12 weeks  
• To determine the effect of treatment with APD334 in inducing clinical response at 12 
weeks  
• To determine the effect of treatment with APD334 on endoscopic improvement at 12 
weeks  
 
This amendment clarifies that the primary endpoint is being changed to a 3-component Mayo 
Clinic Score (stool frequency, rectal bleeding, and findings on endoscopy)  derived from the 
Total Mayo Clinic Score. Thus, the primary endpoint is a continuous variable ranging from 0 
to 9. The rationale for this change is that the endpoin t should be more sensitive to detecting 
clinically important differences between two doses of APD334 and placebo compared to a 
dichotomous complete remission endpoint. Because the trial is considered a proof -of-concept 
trial and dose ranging study, the pri mary endpoint will reflect a broad examination of 
potential clinical improvement across three domains (stool frequency, rectal bleeding, and 
and findings on endoscopy). The secondary endpoints reflect clinical endpoints that are well 
recognized in the clin ical community (complete remission, clinical response , and endoscopic 
score)  and a combination of both clinical  remission and clinical response  reflected by a 
trichotmous endpoint . 
APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
 
Confidential  Page 32 of 101 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
APD334 -003 is a phase 2,  proof -of-concept and dose ranging clinical study designed to test  
the ability of APD334 to induce clinic al response and/or remission in patients with 
moderately to severely active ulcerative colitis . Up to 240 eligible patients will be 
randomized into a d ouble -blind, placebo -controlled study  to receive  once daily (q.d.) doses 
of APD334 (1 mg or 2 mg) or matching placebo  in a 1:1:1 ratio  for 12 weeks.  The screening 
period for the study is up to ~28 days which includes several assessments that must be 
comple ted within 10 days prior to randomization  to ensure eligibility for the study. Patient’s 
vital signs will be monitored using a Holter monitor  for up to 24 hours pre -dose through 24 
hours post  dose. Patients will report daily stool frequency and rectal bleeding using an 
electronic device throughout the study and will be scheduled  at regular intervals for safety, 
, and efficacy assessments. A 34-week extension study  (APD334 -005) is offered to  all 
patients (responders and  non-responders) who complete the study and will meet the relevant 
eligibility criteria . Patients who do not participate in the extension study or who have 
discontinued prematurely from the study will have a 2 -week follow -up visit after the last 
clinical v isit. 
3.2 Study Duration and Dates  
The total study participation/ duration is approximately 18 weeks; ~4 weeks for screening 
procedures, followed by 12 weeks of dosing, and a possible follow -up visit at Week 14.   
The sch edule  of procedures and visit s for the s tudy is provided in  
 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 33 of 101 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 34 of 101 

APD334   Arena Pharmaceuticals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 35 of 101 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 36 of 101 4 STUDY POPULATION SEL ECTION  
4.1 Study Population  
Adult men and women, ages 18 -80 years, who have moderately to severely activ e ulcerative 
colitis  
 
Eligible patients must meet all entry criteria prior to being randomized t o receive study  
medication as outlined below. Any patient -specific concerns or questions regarding these  
criteria must be discussed with the medical monitor or Arena Pharmaceuticals, Inc. prior to  
the patient being randomized.  
4.2 Inclusion Criteria  
Each patie nt must meet the following inclusion criteria to be enrolled in th e study : 
 
6. Moderately to severely active ulcerative colitis defined as  a 3-component  Mayo Clinic  
 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 37 of 101  
 
 
 
7. Evidence of colonic ulcerative colitis activity on endoscopy  
 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 38 of 101  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 39 of 101  
 
4.3 Exclusion Criteria  
Patients meeting any of the following exclusion criteria are not to be enrolled in the study : 
 
4. Within 30 days prior to randomization , receipt of  any of the following for the  treatment 
of underlying disease:  
a. Non-biologic therapies (e .g., cyclosporine, tacrolimus, tofacitinib, thalidomide) other 
than those  specifically listed in  Section  6.12.1 . 
b. A non -biologic investigational therapy  
c. An approved non -biologic therapy in an investigational protocol  
 
5. Within  60 days prior to randomization , receipt of  any of the following:  
a. Infliximab , adalimumab, golimumab, cer tolizumab , vedolizumab  
b. Any other investigational or approved biologic agent  
6. Any prior exposure to natalizumab, efalizumab, or rituximab  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 40 of 101 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 41 of 101 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 42 of 101 5 STUDY TREATMENT(S)  
5.4 Test Article Accountability  
The investigator will maintain accurate records of the receipt of all study medication. In 
addition, accurate records will be kept regarding when and how much study medication is 
dispensed  and used  by each patient  in the study. Reasons for deviation from the expected 
dispensing regimen must also be recorded. Study medication will be reconciled by the Arena  
monitor  or contracted designee . The investigator agrees to provide sufficient access to study 
medication as required for the reconciliation process to be completed in a timely fashion.  
5.5 Investigational Product Retention at Study Site  
At completion of the study, all study medication will be reconciled by the Arena  monitor or 
contracted desig nee and then returned at the direction of the Arena  to be retained or 
destroyed according to applicable country  regulations. Prior to any action being taken with 
study medication after the study is completed, the investigator will contact  Arena (or 
contrac ted CRO) for approval of such action.  
5.6 Dosage and Administration  
Investigational product will be dispensed in a double -blind fashion to the patient s under the 
supervision of the investigator or his/her designee as determined by the randomization 
schedule . All enrolled patients will receive 1 oral dose per day of  1 mg APD334, 2 mg 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 43 of 101 APD334 , or matching placebo for 12 weeks.  
 
 
 
On days with scheduled study visits, p atients should not take their dose of study medication 
at home in order to complete pre -dose study procedures.   
 
5.7 Method of Assigning Patien ts to Treatment Groups  
After signing the voluntary informed consent form (VICF) and completing all screening 
procedures, eligible patients will be randomly assigned in a 1:1:1 ratio to receive 1 of 3 study 
treatments:  
• 1 mg APD334 x 12 weeks  
• 2 mg APD334 x 12 weeks  
• Placebo x 12 weeks  
 
5.8 Randomization and Blinding  
5.8.1  Randomization  
Sites will randomize approximately 240 patients for entry into the study in a 1:1:1 ratio to  
receive once daily doses of 1 mg APD334, 2 mg APD334, or matching placebo  and will be 
stratifie d by presence or absence of current oral corticosteroid usage and previous exposure 
to TNFα antagonists.  The number of patients with previous exposure to TNFα antagonists 
will be capped at 50% (or at most 120 with previous exposure to TNFα antagonists will  be 
randomized).  
5.8.2  Blinding  
The sponsor, patients, and personnel involved with the conduct of the study , with the 
exception of the clinical supply staff , safety staff,  and the unblinded statistician supporting 
the Data Safety Monitoring Board (DSMB) , will be  blinded to the identity of study  
medication.   
In addition, the sponsor, patients, and personnel involved with the conduct of the study  will 
also be blinded to the total WBC and , as access to this information may 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 44 of 101 lead to unintentional unblinding of a patient  (due to Investigational Product’s mechanism of 
action) . A central  CRO physician (s) unblinded to the  and leucocyte counts, but 
blinded to the study medication, will review and monitor the total WBC and  
count s for safety purposes in the trial . The study site personnel will not receive laboratory 
results for the total WBC or . 
5.8.3  Maintenance of Randomization Codes and Code -break Procedures  
The randomization code will be generated by a CRO statistician  not directly involved with 
the study. All other personnel directly related to this study (i.e., investigators, site personnel, 
monitors, CRO personnel, Arena personnel ) with the exception the individuals stipulated in 
Section 5.8.2 , will remain blinded  for the duration of the study. After APD334 -003 has been 
completed, the study will be unblinded to selected individuals (which may or may not 
include:  CRO statistician, Sponsor designate [s], DMPK representative[s]) in order to conduct 
the analyses and reporting for the study.   As these activities will occur while APD334 -005 is 
ongoing, patients, investigators and site will remain blinded to patient -level data of the 
APD334 -003 study until the completion of APD334 -005.  The CRO will obtain written 
consent from Arena prior to breaking the code.  
Breaking of the randomization code without Arena’s permission is expressly forbidden 
except in t he event of a med ical emergency where the identity of the study medication must 
be known in order to properly treat the patient. In the event of a medical emergency, it is 
requested that the investigator make every effort to contact the study monitor or designee 
prior to b reaking the code . If the blind is broken, the individual responsible should document 
the date, time, and reason for breaking the blind. A written communication should be sent to 
Arena within 1 working day.  
5.9 Study Restrictions  
5.9.1  Fluid and Food Intake  
Consumpti on of foods and beverages containing the substances listed below will be 
prohibited as indicated. Exceptions may be permitted upon the joint agreement of the Arena 
and the i nvestigator provided the safety of the patient  and integrity of the study are not 
compromised.  
• Poppy seeds: Consumption of poppy seeds within 48 hours prior to drug screen 
may cause a positive drug screen. Patient s who report that they have consumed 
poppy seeds within 48 hours of the screening visit should not be screened.  They 
may retu rn 48 hours after the last poppy seed consumption for screening.  Poppy 
seeds should not be eaten between screening and Week 0/Day 1  and throughout 
the inpatient period . 
 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 45 of 101 5.10 Data Safety Monitoring Board  
The Data Safety Monitoring Board  (DSM B), independent from Arena, will be established to 
review safety data from this study including, but not limited to, AEs of special interest (e .g., 
bradycardia, infections , PML ) at regular intervals and make recommendations. The roles and 
responsibilities of the DSM B will be outline d in a separate charter.  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 46 of 101 6 STUDY PROCEDURES  
6.1 Informed Consent  
The investigator will obtain and document VICF for each patient  screened for this study.  All 
patient s will be informed in writing of the nature of the protocol and investigational thera py, 
their possible hazards, and their right to withdraw at any time, and will sign a form indicating 
their consent to participate prior to the i nitiation of study procedures. The patient ’s medical 
record should contain written documentation indicating that  informed cons ent was obtained. 
The VICF must be reviewed and approved by the investigator’s designated IRB /IEC  and by 
the sponsor. The VICF should include all the elements as outlined in Section 4.8.10 of the 
ICH guideline for GCP (E6).  
6.2 Medical and Social  History  
At screening, a complete medical history and a social history, including  tobacco , alcohol and 
caffeine use, as well as a full history of UC, will be c ollected by patien t interview. 
Concomitant medications, recent blood donations, illnesses, and pa rticipation in other 
investigational drug studies will also be recorded. A partial examination will be performed at 
check -in to update findings from screening and document any pre -treatment AEs.  
6.2.1  Prior Therapies  
Prior therapies related to UC will be collect ed during screening.  
6.2.2  History of UC  
A detailed history of UC, including date of diagnosis, disease severity, hospitalizations, and  
extraintestinal manifestations will be collected during screening.  
6.3 Physical  and Neurological Examination s 
6.3.1  Physical Examination  
The physical examination  include assessments of general appearance, skin, head (eyes, ears, 
nose, and throat), neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities , 
and body weight  will be performed during by the principal 
investigator or subinvestigator.  A limited examination to assess clinically significant changes 
from the examination performed at screening will be completed during the
visit. Height will only be obtained at screening.  
The p hysic al examination will also include visual acuity and dilated ophthalmoscopy (by an 
ophthalmologist) and with OCT (where available) at screening and visit to rule 
out and monitor for any significant retinal disease, including macular edema. Retin al photos 
will be taken during the screening visit visit and any subsequent unscheduled 
ophthalmoscopy .  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 47 of 101 Safety ECGs will also be performed as outlined in the  schedule of procedures and visits 
( ).  
Clinically significant findings from the physical/neurological examination performed at 
screening will be recorded as medical history. Any new clinically significant findings from 
the time  of screening through the first dose of study drug will be recorded as pre -treatment 
AEs. After the administration of the first dose of study drug, clinically significant findings  
will be recorded as AEs.  
6.3.2  Neurological Examination  
The neurological examination  includes assessments of the neurological system (cranial 
nerves, motor and sensory function, coordination, and mental  status), and will be performed 
during screening,  (limited examination to assess clinically significant changes 
from the screening ), and at  by the principal investigator or subinvestigator. In 
addition, monitoring for progressive multifocal leukoencephalopathy (PML) , a potential 
adverse effect of S1P 1 agonists, will be performed at each site visit (except for the  
) using a subj ective PML checklist .  
The investigator or subinvestigator will administer the subjective PML checklist during 
screening to exclude patients with positive responses from enrolling into the study. The 
subjective PM L checklist will also be administered at each site visit  (except Day  to probe 
for symptoms suggestive of PML. Any patients reporting signs and/or symptoms of PML 
will undergo objective testing and may be referred to a neurologist for a full evaluation.   
Additional information on PML is provided in Section 6.11.1.1  and a  copy of the PML 
checklist is provided in Appendix 1 . 
6.4 Vital Signs  
Supine (laying face upward) blood pressure, heart rate, temperature, and respiratory rate will 
be measured after the patient  has been resting for 5 minutes. Vitals signs will be measured 
prior to any blood draw that occurs at the same time point.  Vital signs will be measured 
according to the time points in the schedule of procedures and visits  ( ).  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 48 of 101 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 49 of 101 6.6 Tuberculosis Screening and Ch est X - ray 
All patients will complete tuberculosis (TB) screening to determine eligibility. All patients 
who do not report a history of TB must complete a diagnostic TB test within  prior to 
randomization  and a chest X -ray within  prior to randomization . (In most countries 
where the BCG vaccine is standard, the TB skin test will likely be positive and a Quantiferon 
test will be needed. ) Patients will be excluded from the study if they have active or latent TB, 
regardless of treatment history , as evidenced by any of the following:  
• History of TB  (that has not been acceptably  treated )  
• A positive diagnostic TB test within 1 month of randomization  defined as:  
- A positive QuantiFERON ® test or 2 successive indeterminate QuantiFERON ® 
tests OR 
- A tuber culin skin test reaction ≥ 10 mm ( ≥ 5 mm in patients receiving the 
equivalent of > 15 mg/day prednisone)  
• Chest X -ray within 12 months of randomization  in which active or latent pulmonary 
TB cannot be excluded  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 50 of 101 6.8 Clinical Laboratory Tests  
All details regarding clinical laboratory sample collection, preparation, and shipment are 
included in the laboratory manual provided by the local or central laboratory and the  
manual provided by Arena . 
In the event of abnormal clinical laboratory values, the physician will make a judgment 
whether or not the abnormality is clinically significant and is deemed an adverse event.   
6.8.1  Laboratory Parameters  
Clinical safety laboratory t ests will be conducted as outlined in   and should be 
completed pre -dose. Laboratory tests will include the following . Complete blood count 
(CBC ) will be obtained prior to dosing. Results of the total white blood cell and  
 will be reviewed and monitored per Section  5.8.2 .  
Serum Chemistry 
Albumin (ALB) 
Alkaline phosphatase (ALK- P) 
Alanine aminotransferase (ALT; SGPT) 
Amylase 
Aspartate aminotransferase (AST; SGOT) 
Bicarbonate  
Blood urea nitrogen (BUN) 
Calcium (Ca) 
Chloride (Cl) 
Creatinine  
Creatine kinase and MB subtype (if 
elevated) (% and total MB) 
Gamma-glutamyl transferase (GGT) Glucose 
Lactate dehydrogenase (LDH) 
Lipase 
Magnesium 
Phosphate  
Potassium (K) 
Sodium (Na) Total bilirubin  
Total cholesterol  
Total protein   
Triglycerides Hematology   
Hematocrit (Hct) 
Hemoglobin (Hb) 
Mean corpuscular hemoglobin (MCH) Mean corpuscular volume (MCV) 
Platelet count 
Red blood cell count (RBC) 
White blood cell count (WBC) with differential 
(% and absolute counts) 
 
Coagulation 
Prothrombin time (PT) Activated partial thromboplastin time (PTT) 
International Normalized Ratio (INR) 
 
Additional tests   
Serum human chorionic gonadotropin (hCG) HIV test 
HBsAg 
Anti- HCV  
VZV IgG  
 
6.8.2  Virology  
Human immunodeficiency virus (HIV antibody), hepatitis B (HBsAg), hepatitis C virus 
(RIBA 2 or 3) , and varicella zoster virus (VZV) IgG antibody  will be performed at  
 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 51 of 101 6.8.3  Drugs of Abuse Screen  
Urine samples for the d rugs of abuse screen will be collecte d according to the laborat ory 
manual provided by the local or central laboratory and according to the schedule of 
procedures and events ( ). 
The drugs of abuse screen wil l include amphetamines, barbiturates, cocaine metabolites, 
opiates, benzodiazepines and cannabinoids.  
6.8.4  Urinalysis  
Urinalysis parameters for clinical laboratory tests include the following:  
• appearance • occult blood 
• bilirubin • pH 
• color • protein 
• glucose • specific gravity 
• ketones  • urobilinogen  
• leukocyte esterase  
 
Microscopic urinalysis will be performed when there is a positive or abnormal macroscopic 
urinalysis result.  
6.8.6  Sample Collection, Storage, and Shipping  
Blood samples for hematology, coagulation parameters, serum chemistry, HIV and hepatitis 
screens, ser um hCG , will be collected according to the laboratory manual provided by the 
local or central laboratory and according to the schedule of procedures and visits ( ). 
6.8.7  Blood Volume  
Total blood volume for clinical laboratory tests during study conduct is less than 1 50 mL. 
6.9 Efficacy Assessments  
6.9.1  Flexible Proctosigmoidoscopy  
A flexible proctosigmoidoscopy, performed with a videoendoscope following a cleansing 
prep (oral or rectal cathartic), will be performed during screening  
 and at Week 12/Exit visit .  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 52 of 101 A repeat flexible proctosigmoidoscopy may be permitted by the sponsor when the central 
reader indicates that the videoendoscope data was acquired incorrectly, or did not meet the 
minimal required quality standards.  
6.9.3  Stool Sample  
A stool sample will be obtained for culture, ova and parasite evaluation  for C. difficile  assay. 
A sample will be collected and cultured during screening a nd at any point in the study when 
a patient becomes symptomatic, including worsening or return of disease activity.   
 
6.9.6  Electronic Clinical Outcomes Assessments (eCOA)  
Patient reported outcomes (stool frequency and rectal bleeding)  will be captured daily using a  
handheld electronic device  from CRF Health call ed a TrialMax Touch Android (HTC Desire 
310).  
During screening, patients will be instructed on how to appropriately complete the electronic 
diary. The symptoms of UC must be recorded throughout the study, including the screening 
period. Diary entries will be reviewed by site personnel during screening and (prior to 
dosing, if applicable) at  
  
The CRF Health eDiary software run s on the device  and includes all the sec urity features  
required of an eCOA solution for 21 CFR Part 11 compliance . 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 53 of 101 6.9.7  Complete Mayo Clinic Score, 3-component  Mayo Clinic Score,  
 
COMPLETE MAYO  CLINIC SCORE (MCS):  SCREENING AND WEEK 12/E XIT ASSESSMENT  
The complete Mayo Clinic Score (MCS) is an i nstrument designed to measure disease 
activity of ulcerative colitis  and consists  of 4 subscores: stool frequency, rectal bleeding, 
findings of flexible proctosigmoidoscopy , and physician global assessment  with each 
component ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).  Total score 
therefore range s from 0 to 12 , with a higher score  indicating more severe disease.  
The MCS will  be evaluated during screening using patient diary entries within the 10 days 
prior to randomizati on and flexible procto sigmoidoscopy results within 10 days prior to 
randomization . The subscores for stool frequency and rectal bleeding are derived from the 
patient diaries. The scores from the 3 most recent days prior to the actual day of the study 
visit will be averaged and rounded to the nearest integer. Note that t he day prior, day of and 
day after procto sigmoidoscopy cannot be used for patient diary entry  because of the required 
bowel prep for the procedure. Patients who have less than 3 days of diary  data during 
screening are not eligible for randomization. Examples of the subscore entries for eligibility 
and subscore derivation are provided in Table  2. The rounding will be applied to each 
subscore prior to the creation of the total score. The MCS  will also be evaluated at 
Week  12/Exit  using the Week 12/Exit proctocsigmoidoscopy and stool frequency and rectal 
bleeding scores completed by the patients up to seven days prior to the visit . 
 
Table  2. Examples of eDiary Subscore Entries for Study Eligibility and 
Corresponding Subscore Derivation  
Example Diary Day Valid Days 
for 
Calculation 
of 
Subscore Average 
Subscore Final 
Subscore 
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 1 
Diary #1 1 2 3 X P X 2 1 3 1 E -1, -2, -3 1.66 2 
Diary #2 2 2 2 3 X P X M 1 3 E -1, -2, -7 2.33 2 
Diary #3 3 2 3 3 3 X P X 3 M E -2, -6, -7 3.00 3 
Diary #4 3 0 1 X P X M M M M E -8, -9, -10 1.33 1 
Diary #5 1 2 X P X M M M M M E Missing N/A Missing 
Abbreviations: E = eligibility; M = missing; P = proctosigmoidoscopy;  X = non -scoring day before and after 
proctosigmoidoscopy  
 
 
3-COMPONENT MAYO  CLINIC SCORE : STUDY ENTRY CRITERIA  AND PRIMARY ENDPOINT  
The 3-component  Mayo Clinic score consists of 3 of the 4 subscores found in the MCS as 
follows: stool frequency, rectal bleeding, and f indings of flexible proctosigmoidoscopy . Total 
score range: 0 to  9, each component ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 
3=severe).  
Entry criteria will be based on a 3-component  Mayo Clinic score (as defined in the inclusion 
criteria).  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 54 of 101 Physician’s Global Assessment (PGA)  
The physician’s global assessment ac knowledges the three other crit eria findings of the 
MCS, the patient’s daily record of abdominal discomfort and ge neral sense of well -being, 
and other observations, such as physical findings and the patient’s performance. The PGA 
will be used in calculation of  the MCS at screening and Week 12/Exit.   
A sample of the complete Mayo Clinic score is provided in  
6.10  and Hematologic  Assessments  
6.10.2  Hematologic  Sampling  
Blood samples for CBC with differential and platelet count will be assessed during  screening, 
and at for those not continuing 
on to the extension study and with abnormal CBC results at exit.    
If the absolute peripheral  has not recovered to at least 80% of the baseline 
value at th  patients  should return for weekly CBCs until the absolute 
peripheral  has returned to at least this value.   

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 55 of 101 All details regarding collection of blood samples for CBC with differential analy sis will be 
collected and prepared according to that specified in the laboratory manual provided 
separately by the central  laboratory.   The samples should be packed and shipped to the 
central laboratory, according to the directions in their laboratory manu al, which will send 
them on to the bioanalytical laboratory for analysis.  
6.10.3  Total Blood Volume  
Total blood volume collected for / hematologic  samples  is less than 120 mL during t he 
study .   
6.11 Adverse Events Assessments  
Patients will be monitored  from  ICF sign ature  to 30 days after the last dose of study drug  for 
adverse reactions to the  study drug and/or procedures.  
AEs will be recorded and reported in accordance with ICH GCP and 21 CFR§312.32. The 
definitions of AEs and SAEs will be as given in the ICH Topic E2A, ICH Guideline “Note 
for Guidance on Clinical Safety Data Management: Definitions and Stand ards for Expedited 
Reporting.”  The outcome of an AE will be defined according to ICH Topic E2B, ICH 
Guideline “Note for Guidance on Clinical Safety Data Managem ent: Data Elements for 
Transmission of In dividual Case Safety Reports.” The relationship to investigational product 
will be classified using the World Health Organization (WHO) criteria.  
6.11.1  Adverse Event Reporting  
Patien ts will be instructed that they may rep ort AEs at any time. AEs that occur from ICF 
signature until  the time of administration of the first dose of APD334  will be regarded as 
‘pre-treatment’  and recorded as an AE. All events reported following study medication 
administration up to 30 days after  the last medication intake will be presented  as treatment 
emergent  AEs (TEAEs)   
Monitoring of AEs will be continued up to 30 days after study medication administration. In 
the event that an AE is not resolved or stabilized by this time, the sponsor in con sultation 
with the investigator will decide whether to continue to monitor the AE or close -out the event 
in the database if no further follow -up is necessary.  
For this study, an AE is defined as: “Any untoward medical occurrence in a study patient  
administ ered any dose of study medication (APD334 or placebo) and which does not 
necessarily have to have a causal relationship with this  treatment.” An AE can therefore be 
any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of the study medication, whether or not related 
to the product. AEs can be any of the following:  
• Unfavorable changes in general condition  
• Subjective or objective signs/symptoms  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 56 of 101 • Concomitant disease or accidents  
• Clinically relevant adverse changes in laboratory parameters observed in a patient  
in the course of a clinical study  
• Pre-existing conditions which worsen in severity or frequency or which have new 
signs/symptoms associated with them  
 
Lymphopenia will not b e captured as an adverse event both to maintain the study blind, and 
also because it is an expected pharmacologic effect of the drug. In order to ensure safe 
conduct of the study  and minimize the risk of study personnel or sponsor becoming 
unblinded to treatment assignment , total WBC and  will be monitored by a 
central  CRO physician (s) unblinded to the  and leucocyte counts. This person 
will remain blinded to the study medication  
Adverse events will be elicited at the time ind icated in the schedule by asking the question: 
“Since you were last asked, have you felt unwell or different from usual in any way?”  Any 
adverse or unexpected events, signs and symptoms, will be fully recorded on the Adverse 
Event Form including details o f intensity, onset, duration, outcome and relationship to the 
drug as determined by the PI.  Whenever possible, a constellation of signs and symptoms 
should be recorded as a unifying diagnosis (e.g., self -limited fever, runny nose, cough, and 
scratchy thro at should be captured as an upper respiratory infection rather than by the 
individual signs and symptoms).  AEs may also be reported at any time. The type and 
duration of follow -up of patient s after AEs will be documented.  
6.11.1.1  Progressive Multifocal Leukoenceph alopathy (PML) Checklist  
A patient with multiple sclerosis developed progressive multifocal leukoencephalopathy 
(PML) after nearly 8 months of treatment with another S1P 1 agonist25, and enablement of the 
John Cunningham (JC) virus is therefore a potential adverse effect of this therapeutic class. 
Patients in this trial should therefore be monitored for any new onset or w orsening  of 
neurological signs and  symptoms. S igns and symptoms associated with PML are diverse, 
progress over days  to weeks, and include progressive weakness on one side of the body or 
clumsiness of limbs, disturbance of vision, and changes in thinking, m emory, and orientation 
leading to confusion  and personality changes. The progression of deficits usually leads to 
death or severe disability  over weeks or months. If PML is suspected, withhold dosing and 
refer to a  neurologist; if confirmed, discontinue dosing permanently.  
The investigator or subinvestigator will administer the subjective PML checklist during 
screening to exclude patients with positive responses from enrolling into the study. The 
subjective PML checklist will be administered at to probe for 
symptoms suggestive of PML. Any patients reporting signs and/or symptoms of PML will 
undergo objective testing and may be referred to a neurologist for a full evaluation.  
A copy of the PML checklist is provided in Appendix 1 . 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 57 of 101 6.11.2  Serious Adverse Events and Expedited Reporting of Adverse Events  
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results 
in the following outcomes:  
• Death  
• Is Life -Threatening  
• Required/Prolonged Hospitalization  
• Disability/Incapacity  
• Congenital Anomaly/Birth Defect  
• Important Medical Event  
SAEs will be captured from the time of  ICF signature  to 30 days after the last dose of study 
drug, and will be monitored until resolution or stabilization.  
An important medical event that may not result in death, be life -threatening, or require 
hospitalization may be considered a SAE when, based upon appropriate medical judgment, it 
may jeopardize  the patient  and may require medical or surgical intervention to prevent one of 
the outc omes listed in this definition.  Examples of such a medical event includes allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias, or convulsions that do not result in in -patient  hospitalization, or the development 
of drug dependency or drug abuse.  
Elective hospitalization and/or surgery for clearly pre -existing conditions (for example a 
surgery that has been scheduled prior to the patien t’s entry into the study)  will not be 
reported as a SAE.  All other hospitalizations, including elective hospitalizations for any 
condition that was not pre -existing, will be reported as a SAE.   
Any AE considered serious by the investigator or  which meets SAE criteria must be reported 
to PPD Pharmacovigilance (PVG) using the remote data capture (RDC) system within 
24 hours from the time study site personnel first learn about the event . The following contact 
information is to be used for SAE rep orting:  
 
PPD  Medical Affairs/Ph armacovigilance  
PPD PVG Hotline  EMEA and APAC :  
PPD PVG Hotline NA: 
PPD PVG Fax line:  
 
In the event that RDC entry is not possible (e.g., system failure or access problems), the 
study site should complete the paper SAE report form and fax the form to PPD PVG within 
24 hours of awareness of the event. The RDC system should be updated as soon as it is 
available.  
A full description of every serious adverse event will need to be provided to PPD PVG (this 
may be supported by source documentation such as laboratory reports or a discharge 
summary should the patient be hospitalized).  
 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 58 of 101 Other safety issues as defined in ICH Topic E2A, 21 code of federal regulations (CFR) 
§312.32, and EU Volume 10 also qualify for expedited reporting. In these situations the 
process will be as detailed for SAEs above:  
• SAEs which could be associated with the trial proce dures;  
• SAEs and AEs of special interest that could materially influence the benefit -risk 
assessment of a medicinal product, such as: a clinically important increase in the 
rate of a serious suspected adverse reaction over that listed in the investigator 
brochure.  
 
6.11.2.1  Patient and Patient -partner Pregnancy  
Patients  who become pregnant during the study will be discontinued immediately. Although 
not considered a n SAE or AE, pregnancies occurring during the period of study drug 
administration of study drug should 
be reported to the sponsor contact and IRB /IEC  in the same manner as a n SAE.  
Pregnancies will be followed every trimester thro ugh the first well baby visit. For female 
partners whom become pregnant b y male study patient s during the course of the study, 
reasonable efforts will be made to collect information on the partner’s pregnancy through the 
first well baby visit as provided by the male study patient . 
6.11.3  Assessment of Adverse Event Severity  
The severi ty of each AE will be assessed at onset by a nurse and/or  physician. When 
recording the outcome of the AE the maximum severity of the AE experienced will also be 
recorded. The severity of the AE will be graded according to the CTCAE v4.0322 definitions,   
listed below:  
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observ ations only; 
intervention not indicated.  
Grade 2:  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental Activities of Daily Living (ADL)*.  
Grade 3:  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care 
ADL**.  
Grade 4:  Life-threatening consequences; urgent intervention indicated.  
Grade 5:  Death  related to AE.  
Activities of Daily Living (ADL) : 
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 59 of 101 **Self-care ADL refer to bathing, dressing and undressing, feeding self, using the to ilet, 
taking medications, and not bedridden.  
 
6.11.4  Assessment of Adverse Event Relationship to Study Medication  
The relationship of an AE to investigational product(s) will be classified using modified 
WHO criteria (Edwards and Biriell, World Health Organizati on Collaborating Centre for 
International Drug Monitoring 1994) as follows.  
Related :  a clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease or  
other drugs or chemicals, and which follows a clinically reasonable response on withdrawal 
(dechallenge). Rechallenge information is not required to fulfill this definition; or an event 
that could also be explained by concurrent disease or other drugs or chemicals where 
information on drug withdrawal may be lacking or unclear.  
Not related :  a clinical event, including laboratory test abnormality, with sufficient evidence 
to accept that there is no causal relationship to drug administration (e.g., no tempor al 
relationship to drug administration, because the drug was administered after onset of event; 
investigation shows that the drug was not administered; proof of other cause; etc.); or an 
event with a temporal relationship to drug administration which makes  a causal relationship 
improbable, and in which other drugs, chemicals or underlying disease provide plausible 
explanations.  
6.11.5  Assessment of Adverse Event Outcome  
Outcome of AEs will be defined according to ICH Topic E2B, ICH Guideline.  
• Recovered/Resolved  
• Recovered/Resolved with Sequelae  
• Recovering/Resolving  
• Not Recovered/Not Resolved  
• Fatal  
• Unknown  
 
6.11.6  Action Taken for Adverse Event  
Action taken for AEs will be documented according to the following:  
• Concomitant medication or other treatment  
• Withdrawal from the study  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 60 of 101  
6.11.7  Action Taken for Study Drug  
Any action taken with study drug will be defined according to ICH Topic E2B, ICH  
Guideline and documented in the CRF according to the following:  
• Drug Withdrawn  
• None (not changed)  
• Dose Interrupted  
• Unknown  
• Not Applicable  
 
6.11.8  Collection of Extra Laboratory Samples/Investigations  
In the event of a clinically important AE, a suitable sample may be collected for drug assay 
or fo r additional laboratory tests. The investigator must ensure that the sample i s properly 
labeled and stor ed. The investigator and others responsible for care of the patient  should 
institute any supplementary investigations of significant AEs based on the clinical judgment 
of the likely causative factor. This may include seeking a further opinion from a spec ialist in 
the field of the AE. The company may suggest special tests based on expert advice.  
6.11.9  Follow -up of Adverse Events Present at Last Scheduled Study Visit  
Adverse events present at the last study day ( Week 12/E xit) that require follow -up or a repeat 
laboratory test will be followed -up initially for 30 days according to the site’s standard 
practice  for AE follow -up. AEs that have not resolved or stabilized at 30 days after the last 
patient ’s last study dose, will be reviewed with the sponsor on an individu al basis to 
determine whether the database will be locked and subsequently updated once the events of 
ongoing AEs are resolved or whether database lock will be held.  
6.12 Concomitant Medications  and Procedures  
All medications (OTC and prescribed) that are taken  by patients and all procedures that are 
performed during the screening period and during the study must be recorded in the 
electronic case report form (eCRF) with start date/time and stop date/time, if known.  
Concomitant medication for medical conditions  other than UC are permitted as clinically 
indicated patient  to specific protocol requirements outlined in Section 4.2 and Section 4.3. 
The following should be taken into account with regard to concomitant procedures:  
• Patients may not undergo major elective surgery while enroll ed in this study.  
• Patients may not donate sperm, or oocytes during the study and for 30 days after 
the last dose of study drug.  
 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 61 of 101 6.12.1  Permitted  Medications  for the Treatment of UC  
Oral 5 -ASA treatment is permitted for the treatment of UC, provided that the patient was 
receiving the medication(s) at baseline, and that the dose(s) ha s been stable as specified in 
Section 4.2. These medications should remain stable throu ghout the study.  
Oral corticosteroids that the patient is receiving at baseline may be continued, provided that 
the dose has been stable for the 4 weeks immediately prior to  screening endoscopy 
assessment if corticosteroids have just been initiated  as specified in Section 4.2. These 
medications should remain stable throughout the study  (tapering may be initiated after 
participation in this study or during extensi on study APD334 -005).  
Azathioprine or 6 -mercaptopurine , provided that the dose has been stable for the 8 weeks 
immediately prior to screening. ( These immunosuppressive agents must be discontinued 
at the time of randomization .) 
Probiotics (e.g., Culturelle , Saccharomyces boulardii ) provided that the dose has been stable 
for the 2 weeks immediately prior to randomization . 
Antidiarrheals are allowed throughout the study as necessary for control of chronic diarrhea; 
stable doses are encouraged.  
6.12.2  Excluded  Medica tions  
The following medications are excluded from the study:  
• Treatments for UC other than those listed in Section 6.12.1  (either approved or 
investigational)  
• All live vaccines, during study treatment and for at least 6 months  after the last dose 
of study drug  
• Moderate to strong inhibitors of CYP2C9  
 
6.13 Removal of Patients from the Trial or Study Drug  
The study may be terminat ed early if, in the opinion of the sponsor, investigator, or IRB/IEC,  
an unacceptable risk to the safety and welfare of patients is posed by the continuation of the  
study in light of review of the key safety data.  
Patients will be free to withdraw from the  study at any time should  they so wish. A patient 
may be withdrawn from the study for any of the following reasons  (including but not limited 
to): 
• Clinical investigator may remove a patient if, in his/her opinion, it is in the best 
interest of the patient  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 62 of 101 • Withdrawal of consent - Any patient may withdraw his/her consent from the study at 
any time. The investigator should make a reasonable attempt to document the specific  
reason why consent was withdrawn.  
• Deviation/noncompliance with the protocol or study dru g 
• An adverse event  
• Lost to follow up  
 
6.13.1  Handling of Withdrawals  
Although a patien t is not obliged to give his/her reason fo r withdrawing prematurely, the 
investigator will make a reasonable effort to obtain the reason while fully respecting the 
patient ’s rig hts. If there is a medical reason for withdrawal, the patien t will remain under the 
supervision of the study physician until in satisfactory health. Reasonable efforts will be 
made to contact a patient  who fails to attend any follow -up appointments, in ord er to ensure 
that he/she is in satisfactory health.  
If a patien t is prematurely discontinued from this study, every attempt will be made to follow 
the Week 12/ Exit visit procedures described in Section  7.4.4 . 
6.13.2  Replacements  
Patients who terminate early from the study will not be replaced.  
6.14 Allowable Visit and Procedure Windows  
• 
If screening  process is interrupted due to technical issues (timing, medical devices 
functioning etc.) , patient can continue the screening after the have passed , but 
time extension must not exceed  In 
this case , all medical evaluations performed previously are considered still valid , 
except for the following procedures, which have to be performed  within
to randomization : 
- Flexible proctosigmoidoscopy with  
- Diary review  
- Complete Mayo score (MCS)  
- Reco rd adverse events  
- Record concomitant medications/procedures  
-  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 63 of 101 • There are no visit windows after randomization . 
 
6.15 Study and Site Discontinuation  
The Sponsor has the right to terminate this study at any time.  Reasons for terminating the 
study may include, but are not limited to, the following:  
• The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to patients.  
• Patient enrollment is unsatisfactory.  
• The Sponsor will notify the investigator if the study is placed on hold, or if the 
Sponsor decides to discontinue the study or development program.   
 
The Sponsor has the right to replace a site at any time.  Reasons for replacing a site may 
include, but a re not limited to, the following:  
• Excessively slow recruitment  
• Poor protocol adherence  
• Inaccurate or incomplete data recording  
Non-compliance with the ICH guidelines for GCP  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 64 of 101 7 STUDY ACTIVITIES  
 
At the initial screening visit, potential patient s will have a detailed oral presentation of the 
nature, purpose, risks, and requirements of the study in addition to receiving  detailed written 
information. They will have adequate opportunity to ask the appropriate person of the clinical 
staff (i.e., principal investigator or designee) presenting the study  about any aspect of the 
study.  Once the patient  is satisfied that he/she is willing to participate in the study, he/she 
will be  asked to sign the study VICF. The clinical personnel obtai ning written consent from 
the patient  will also sign the form to conf irm consent has been obtained. Once signed, the 
investigator will retain the original for the patient ’s study records and provide the patient 
with a signed copy. The investigator will verify that informed consent has been obtained 
from each patien t prior to admission into the study and prior to the patien t undergoing any 
study -related procedures.  If it is standard practice at the site to conduct a few general non -
invasi ve study procedures (i.e., medical/social history, collection of concomitant 
medications, etc.) before a patien t can be considered for a specific study, the study center 
must have a written SOP detailing the procedure, and also ensure that each patien t signs a 
general consent prior to undergoing the general procedures.  
A unique patient  screening number will be assigned upon completion of the VICF.  
Within 2 8 days before administration of the study medication, or sooner, all screening 
activities subsequent to  obtaining informed consent will be conducted and consist of the 
following : 
• Review of all inclusion and exclusion criteria  
• Collection of demographic data (sex, age, race/ethnicity)  
• Completion of medical and social history (to include tobacco, alcohol, and  caffeine 
use) 
• UC medical history  
• Physical /neurological  examination, including height, weight, vital signs (i.e., supine 
blood pressure, heart  rate, respiration s, and temperature after a 5 minute rest) and 
ophthalmoscopy  with OCT  (where available)  and reti nal photos  
•  
• PML checklist  
• Safety ECG  (12-lead)  
• Pulmonary function test (spirometry)  
• Stool sample  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 65 of 101 •  
• TB screening  
• Chest X -ray, Posteroanterior (PA) and Lateral  (per ) 
• Clinical laboratory tests ( hematology, serum chemistry, coagulation parameters, 
urinalysis, , and drugs of abuse screen), and virology screen (HBsAg, HIV 
antibodies, and HCV antibodies).   
• CBC with differential and platelet count  
• Serum hCG pregnancy test ( non-postmenopausal females only)  
• Diary instruction  
• Record adverse events  
• Record c oncomitant medications /procedures  
 
The following activities must occur with in 10 days prior to randomization :  
• Flexible proctosigmoidoscopy with   
• Diary review  
• Complete Mayo Clinic score  (MCS)  
• Record adverse events  
• Record c oncomitant medications /procedures   
Extension of screenin g time -window (up to 35 days)  might be allowed , and performed as p er 
Section 6.14. 
 
7.2 Screening Failures  
A screening failure is defined as a patien t who has signed the VICF, does not meet all the 
entry criteria as outlined in this protocol and has not been randomized or received study 
medication .  
7.2.1  Re-screening  
In case of screening failure  (e.g. due to low ulcerative colitis severity, temporary intestinal 
infection, concomitant medication etc.) , a patient can be re -screened. During re -screening, if 
not feasible f or the patient, ophthalmology and p ulmonary function t ests do not have to be 
repeated i f the last assessment  was not done longer than three months  before . All other 
assessments have to be repeated.  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 66 of 101 7.3  Holter Fitting and Monitoring  
Patient s who meet all the entry criteria and are eligible for the study will report to  the site on 
the morning of  to receive their Holter monitor for the
 monitoring period. Patients will be monitored on site to confirm the monitor is 
working correctly before being released to return on  
7.4 Treatment Period  
  
• Medical history (partial history, to update findings from screening and document any 
pre-treatment AEs)  
• Physical  and neurological  exam (limited examination to assess clinically significant 
changes from screening)   
•  
• Holter monitoring  (per ) 
• PML checklist  
• Clinical laboratory tests (serum chemistry, hematology, coagulation parameters, 
urinalysis  and ) (per ) 
• CBC with differential and platelets  (per ) 
•  
• Drugs of abuse screen (to include  amphetamines, barbiturates, cocaine metabolites, 
opiates, benzodiazepines and cannabinoids).  
• Urine pregnancy test (women only)  
•  
. 
• Diary review  
•   
• Vital signs  (per ) 
• Drug dispensation  
• Record adverse events  
• Record concomitant medications / procedures  
• Randomization  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 67 of 101 • Study drug administration  (per ) 
 
7.4.2  At-home Holter Removal  
Patients will remove their Holter monitors after the monitoring periods 
have completed (on . Removal time and instructions will be provided to  the patient by 
the site .  For convenience, the p atient s may return the Holter monitor at the next  visit. 
• Safety ECG (12-lead) (per ) 
• PML checklist  
• Clinical laboratory tests (serum chemistry, hematology, coagulation parameters, 
urinalysis  and ) (per ) 
• CBC with differential and platelets  (per ) 
• Urine pregnancy test (women only)  (per ) 
•  
• Diary review  
•  
• Stool sample  per ) 
•  
• Vital signs  (per ) 
• Study drug dispensation/ administration (per ) 
• Drug accountability  
• Record adverse events  
• Record concomitant medications / procedures  
• Physical / neurological  exam  and ophthalmoscopy  with OCT  and retinal photos (per 
) 
• Safety ECG  (per ) 
• PML checklist  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 68 of 101 •  
• Pulmonary function test (spirometry)  (per )  
• Clinical laboratory tests (serum chemistry, hematology, coagulation parameters, 
urinalysis  and ) 
• CBC with differential and platelets  (per ) 
• Serum  pregnancy test (women only)  
•  
• Diary review  
• Flexible proctosigmoidoscopy with   
• Complete Mayo Clinic score (MCS)  
• Determine clinical responder/non -responder status of patient based on the following  
criteria:  a decrease (from baseline) in 3-component  Mayo Clinic score of ≥ 2 points 
and a decrease of  ≥ 30% with  either a decrease of rectal bleeding of ≥ 1 or rectal 
bleeding score of 0 or  1 at Week  12. 
• Stool sample  
•  
• Vital signs  
• Study drug administration (per ) 
• Drug accountability  
• Record adverse events  
• Record concomitant medications / procedures  
Patients who do not wish to continue in to the extension study will have a
visit after their final visit t o have additional safety assess ments performed as outlined in the 
schedule of procedures and visits ( ). 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 69 of 101 8 DATA MANAGEMENT  
8.1 Data Collection  
All data (ECGs, clinical laboratory data, and all other study -related data) will be collected 
according to the sponsor or CRO’s SOPs.  
Upon database lock, which occurs after resolution  of all queries , the CRO, if applicable, will 
provide statistical analysis software (SAS) transfer datasets to the sponsor and to the 
biostatistician for analysis using secure electronic data transfer per the sponsor’s 
specifications.  
8.2 Data Coding  
8.2.1  Adverse E vents  
Adverse events will be coded using the most current Medical Dictionary for Regulatory 
Actvities  (MedDRA) and tabulated, including categorical information of interest such as 
onset and resolution times, time of onset relative to dose, severity at onse t, maximum 
severity, causal relationship to study medication, and action  taken. Whenever possible, a 
constellation of signs and symptoms should be recorded as a unifying diagnosis (e.g., self-
limited  fever, runny nose, cough, and scratchy throat should be captured as an upper 
respiratory infection rather than by the individua l signs and symptoms). AEs will be regarded 
as ‘pre -treatment’ if they occur between screening and the time of administration of the first 
dose of APD334 . All other AEs that occur after  the first dose of study medication will be 
considered to be ‘treatment -emergent’.  
8.2.2  Concomitant Medications  and Non -drug Treatments  
Due to the variability in how medications are recorded, a standard naming convention is 
required in order to t abulate this da ta effectively. A common method of standardization is to 
categorize medica tions by their Preferred Term. In order to do this, medications will be 
coded using the World Health Organization Drug Dictionary (WHODRUG), Format C.  
8.2.3  Medical History  
Medical history  will be coded using the most current MedDRA (version  18.0 or later).   
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 70 of 101 9 PLANNED STATISTICAL METHODS  
The statistical analysis of the data obtained from this study will be the responsibility of the 
CRO . The intention  of Section 9  is to provide overview of st atistical analyses.  Details of the 
statistical analyses and statistical testing procedure will be included in a separate statistical 
analysis plan (SAP) which will be finalized before database lock.  If, after the study has been 
unblinded , changes are mad e to the pre -specified statistical analysis plan, the changes will be 
listed along with an explanation as to why they occurred in the Clinical Study Report.  
9.1 Hypothes es and Objectives  
9.1.1  Objectives  
9.1.1.1  Primary Objective  
The primary objective of this proof -of-conce pt study will be to determine the effect of 
treatment with APD334 in improving 3 -component Mayo Clinic Score (score ranging from 0 
to 9, including stool frequency, rectal bleeding and findings on endoscopy) at Week 12.  
9.1.1.2  Secondary Objective(s)  
The secondary objectives of the study are:  
• To determine the effect of treatment with APD334 on a combination of clinical 
remission and clinical response reflected by a composite endpoint at 12 weeks  
• To determine the effect of treatment with APD334 in inducing clinical remission at 
12 weeks  
• To determine the effect of treatment with APD334 in inducing clinical response at 12 
weeks  
• To determine the effect of treatment with APD334 on endoscopic improvement at 12 
weeks   
 
9.1.1.3  Safety  Objective  
The safety objective of this study is  to determine the safety profile and tolerability of 
APD334 induction treatment.  
9.1.1.4  Exploratory  Objective(s)  
The exploratory objectives of the study are:  
• To determine the effect of APD334 treatment  on Total Mayo Score at 12 weeks.  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 71 of 101  
9.1.2  Hypotheses  
9.1.2.1  Primary Hypothesis  
In patients with moderately to severely active ulcerative colitis, treatment with APD334 
compared with placebo will provide greater improvement in 3-component Mayo Clinic S core 
at 12 weeks.   

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 72 of 101 9.1.2.2  Secondary  Hypothes es 
• In patients with moderately to severely active ulcerative colitis, treatment with 
APD334 compared with placebo will provide better combination of c linical remission 
and clinical response reflected by a composite endpoint at 12 weeks.  
• In patients with moderately to severely active ulcerative colitis, treatment with 
APD334 compared with placebo will provide more patients that achieve clinical 
remission  at 12 weeks . 
• In patients with moderately to severely active ulcerative colitis, treatment with 
APD334 compared with placebo will provide more patients that achieve clinical 
response  at 12 weeks . 
• In patients with moderately to severely active ulcerative colitis, treatment with 
APD334 compared with placebo will provide more patients that achieve endoscopic 
improvement at 12 weeks.  
 
9.2 Sample Size  and Power Calculations  
For the comparison of the proportion of patients who achieve clinical remission between 
APD33 4 versus placebo, a sample of ~80 patients per group will provide 80% power to 
detect a difference of 18% (from 10% to 28%) at α=5% (2 -sided test). This calculation is 
based upon a n assumed  placebo rate of 10%.  
9.3 Analysis Populations  
The analyses of all proportion based efficacy variables will use the Intent -to-Treat (ITT) 
population as primary.  For other continuous efficacy endpoints, the Modified Intent -to-Treat 
(MITT) population will be used as primary. A completer’s population wil l be used as a 
secondary analysis population for the primary endpoint , secondary endpoints  and other 
efficacy endpoints .   
INTENT -TO-TREAT POPULATION (ITT):  
This population consists of all randomized patients, who received at least 1 dose of study 
medicati on. Under this approach, patients are counted in the treatment group to which they 
were randomized, regardless of the treatment received during the course of the trial.  
MODIFIED INTENT -TO-TREAT POPULATION (MITT):  
This population consists of all randomized patients, who received at least 1 dose of study 
medication, have a baseline measurement, and have a t least one  post-randomization 
measurement.  Under this approach, patients are counted in the treatment group to which they 
were randomized, regardless of th e treatment received during the course of the trial.  Note that 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 73 of 101 MITT population can vary with endpoints since some patients may have the needed data for 
inclusion in the MITT population for some endpoints but not for others . 
COMPLETERS POPULATION (CP):  
This population consists of all patients who completed the study. No missing data will be 
imputed for this analysis. Any substantial differences between conclusions based on the 
ITT/MITT  population and the completers’ population will be investigated.  
SAFETY  POPULATION (SP): 
The Safety Population will include all randomized patients who received study medication.  
9.4 Demographics and Baseline Characteristics  
All baseline patien t characteristics of demographic data (age, height, weight, race), ulcerative 
colitis history, social history (smoking status, caffeine intake, alcohol intake), medical history 
(abnormalities only), physical examination (abnormalities only), and concomitant 
medications at study entry will be listed for all patient s. 
Demog raphic data wil l be summarized and tabulated. Continuous variables will be 
summarized using number of observations (n), mean, standard deviation (SD) , median, 
minimum, and maximum.  Frequencies and percentages will be reported for all categorical 
data.  
9.5 Efficacy Endpoints  
Primary:  
• The improvement of 3 -component Mayo Clinic S core (score ranging from 0 to 9, 
including stool frequency, rectal bleeding and findings on endoscopy) at Week 12.  
 
Secondary:  
• The t richotomous composite score of clinical remission and clinical response (score 
ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 
for only achieving clinical response, and 0 for achieving neithe r) at Week 12.  
• The proportion of patients achieving clinical remission [defined as individual 
subscores of the 3 -component Mayo Clinic score as follows: an endoscopy score 
(using flexible proctosigmoidoscopy)  of 0 or 1, a rectal bleeding score of 0, and a 
stool frequency score of 0 or 1 with a decrease of ≥ 1 point from baseline subsc ore at 
Week  12 
• The proportion of patients who achieve  clinical re sponse  [defined as a d ecrease in 3-
component  Mayo Clinic score of ≥ 2 points and  a decrease of ≥ 30% with either a 
decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or  1] at Week 12 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 74 of 101 • The p roportion of patients who achieve  endoscopic improvement  [defined as Mayo 
endoscopic subscore (using findings of flexible proctosigmoidoscopy ) of ≤ 1 point ] at 
Week 12  
 
Exploratory:  
• Improvement in Total Mayo Clinic S core (score ranging from 0 to  12, including stool 
frequency, rectal bleeding and findings on endoscopy, and physician’s global 
assessment) at Week 12  
 
9.6 Statistical Methods  
9.6.1  Primary Efficacy Analysis  
The primary analysis will be based on the change from baseline in 3-component Mayo Clinic 
Score at Week 12 using an analysis of covariate (ANCOVA) model with terms for trea tment, 

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 75 of 101 current oral corticosteroid use, prior exposure to TNFα antagonists and baseline value as 
covariate .  Least -squares mean (LSM) by treatment group and its 95% confidence interval 
(CI), and least -squares mean difference between treatment group and its  95% CI will be 
reported.  
 
Mayo Clinic Score data handling: f or each study visit during the study (excluding the 
screening/baseline visit which uses 10 prior days),  stool frequency and rectal bleeding 
subscores will be derived from electronic patient diari es completed over the 7 days prior to a 
study visit. Note that the day prior, day of and day after proctosigmoidoscopy will not be 
used for patient diary entry because of the required bowel prep for the procedure. These 
subscores will be calculated using t he following rules:  
 
1. The scores from the 3 most recent days prior to the actual day of the study visit  will 
be averaged and rounded to the nearest integer.  
2. If patient diary entries from 3 days are not available, the scores from the 2 most 
recent  entries will be averaged and rounded to the nearest integer.  
3. If less than 2 days of diary data are available, the subscore will be considered 
missing . 
 
The rounding will be applied to each subscore prior to the creation of the total score.  
 
9.6.1.1  Secondary and Exploratory Efficacy Analyses  
The secondary analyses include following:  
 
• Trichotomous composite score of clinical remission and clinical response at Week 12  
is an ordinal categorical endpoint with 3 scores (2, 1, 0).  It will be analyzed using 
Cochran -Mantel -Haenszel method  adjusted for the stratification factors of presence or 
absence of current oral corticosteroid therapy at baseline and previous exposure to 
TNFα antagonists , and using modified ridit score to compute testing statistic and p -
value for between -treatment comparison.  
• The proportion of patients who achieve  clinical remission , clinical response, and 
endoscopic improvement  will be analyzed individually using Cochran -Mantel -
Haenszel (CMH) test adjusted for the stratification factors of presen ce or absence of 
current oral corticosteroid therapy at baseline and previous exposure to TNFα 
antagonists, to compare  the difference of proportions between treatment group . The 
CMH stratified risk difference and its 95% confidence interval will be provide d. 
 
All patients who prematurely discontinue for any reason will be considered failures (non -
responders) for all the proportion based endpoints.  To assess the robustness of the results, 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 76 of 101 several imputation/sensitivity analyses will be performed  (i.e. comple ters population; more 
details will be specified in the SAP).  
Exploratory efficacy analyses  
 
 
 
 
Dose response analyses will be performed using ANCOVA model for continuous variables, 
or logistic regression model for categorical variables , as appropriate .  Treatment group and 
appropriate baseline covariates will be include d in the analysis model.  Statistical te sting of 
dose response trend will be based on appropriate contrast statement assuming  monotonic 
dose response profile in placebo, APD334 low dose and APD334 high dose.  
For the repeated measures analysis, no explicit imputations will be made for this approach.  
Missing data are assumed to be missing at random (that is, ignorable missingness), which 
means that the missingness of the data does not depend on the value that is missing after 
adjusting for the effect of the data that are observed.  
An analysis of covariance (ANCOVA) with LOCF imputation for missing data will be 
performed for Week 12 change from baseline in the complete Mayo Clinic Score,  
 
 The 
ANCOVA model will include terms for treatment, current oral corticost eroid  use, previous 
exposure to TNFα antagonists  and baseline value as a covariate.  
9.6.2  Subgroup Analyses  
Subgroup analyses for the primary efficacy endpoint will be performed in order to explore 
whether the treatment effects are consistent across different s ubgroups. The baseline patient 
characteristics below are the subgroup factors to be explored.  
• Sex (Male, Female)  
• Age: > or ≤ median age, ≥ or < 65 years  
• Race  
• Presence or absence of  current oral corticosteroid use   

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 77 of 101 • Previous exposure to TNFα antagonists   
•  
•  
 
In addition to the subgroup analyses for the primary endpoint, the following analyses will be 
performed:  
• 
 
 
•  
 
9.6.3  Multiplicity  
A statistical  testing procedure will be constructed to manage multiplicity issues concerning 
primary and secondary efficacy analyses in order to control overall Type I error rate for 
efficacy testing  not exceeding 0.05. The details of testing procedure will be specified in a 
separate SAP. 
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 78 of 101    
9.6.4  Interim Analysis  
Sponsor may plan an unblinded interim analysis at time when sufficient number of  patients 
have finished 12 weeks of treatment. If Sponsor decid es to perform an interim analysis, it  
will be operated by an independent Data Review Committee (DMC).  The revision of 
statistical analysis plan (SAP) with detailed interim analysis specifications and a DMC 
charter will be provided to regulatory agency in timely manner and will be finalized prior to 
the interim analysis.  
9.6.5  Data Safety Monitoring Board  
The DSMB will monitor emerging study safety data and has the  responsibility to review 
specific safety data reports, and to  request additional reports as needed.  Unblinded data 
reports generated by the unblinded statistician will be reviewed for  adverse treatment effects 
and patient  safety.  The DSMB must keep results from blinded and unblinded data reports 
confidential.  The roles and responsibilities of the DSMB will be outlined in a separate 
charter.  
9.8 Safety Analysis  
Safety and tolerability will be assessed by a review of all safety parameters including adverse 
experiences (AEs), laboratory safety parameters, vital signs, and ECG. Only summary 
tabulations (N, mean [or median], SD, mean [or median] change/percent change) and 95% 
CIs for between -group differences will be obtained. Adverse experiences will only be 
presented as summary tabulation s. The analyses for all safety outcomes (categorical or 
continuous measures) will use the safety population which consists of all randomized patients 
who received at least 1 dose of study drug; in addition, if a patient is found to have taken a 
study thera py for the entire duration of the study different from that to which he/she was 
randomized, then the patient is counted in the treatment group of the drug he/she actually 
received.  
For analysis based on laboratory measurements, at least 1 laboratory test p ost-randomization 
is required for inclusion in the safety population. When assessing change from baseline, a 
baseline measurement is also required. Baseline for the safety analysis is defined as the last 
pre-randomization measurement. No missing data will be imputed for the safety analysis.  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 79 of 101 9.8.1  Adverse Events  
Adverse events will be coded using the most current Medical Dictionary for Regulatory 
Activities  (MedDRA) and tabulated, including categorical information of interest such as 
onset and resolution times, time of onset relative to dose, severity at onset, maximum 
severity, causal relationship to study  medication, and action taken. AEs will be regarded as 
‘pre-treatment’ if they occur between Screening and the time of administration of the first 
dose of APD334 . All other AEs that occur after the first dose of study medication will be 
considered to be ‘treatment -emergent’.  
Treatment -emergent AEs (TEAE) wi ll be listed by patients and by treatment. They will be 
summarized per treatment and expressed in terms of maximum severity and relationship to 
study medication. The incidence of TEAEs classified according to system organ class will be 
summarized by treatm ent group. TEAEs will also be summarized by maximum intensity 
(assessed according to the Common Terminology Criteria for Adverse Events v4.0313 
definitions) and relatedness to study medication.  
Summaries of the number (%) of patients in each treatment grou p with at least 1 TEAE, 
classified according to MedDRA system organ class and preferred term, will also be 
provided for:  
• Drug -related TEAE  
• Treatment -emergent AEs leading to permanent discontinuation of study medication 
(study medication discontinued or wit hdrawal from study).  
• Serious adverse events (SAEs)  
Serious adverse events will be listed by patient and by treatment. If there are no SAEs at the 
end of the study, the tables or listings will state that there are no SAEs in the study.  
9.8.2  Physical Examinations  
Physical examination results (abnormalities only) at each study visit  will be listed.  
9.8.3  Concomitant Medication  
Pre-treatment and concomitant medication administered during the study will be listed. 
Concomitant medications will be coded using the WHODRUG Dic tionary.  
9.8.4  Vital Signs  
Individual vital sign measurements will be listed by treatment summarized  using descriptive 
statistics. Summary statistics will also be provided for change from baseline in vital sign 
measurements by  treatment .  Baseline is defined as the last pre -randomization measurement.  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 80 of 101 9.8.5  Clinical Laboratory Values  
Individual lab values will be listed by treatment and visit, and summarized using descriptive 
statistics. Summary statistics will also be provided for change from baseline in lab values.  
Baseline is defined as the last pre -randomization measurement . Shift tables from baseline to 
last double -blind visit will also be produced for the laboratory assessments based on the 
categories of Low, Normal, and High. A clinically significant change from b aseline may be 
recorded as an AE if deemed appropriate by the PI or sponsor.  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 81 of 101 10 REGULATORY REQUIREME NTS 
10.1 Pre-Study Documentation  
The sponsor must receive the following documentation prior to initiation of the trial:  
• Protocol signature page signed and dated by the principal investigator (PI)  
• FDA form 1572 signed and dated by the PI  
• Curriculum vitae of the PI and subinvestigators, updated within 2 years  
• Current medical licenses for the PI and all subinvestigators  
• Financial disclosure form signed by the PI and a ll subinvestigators listed on the FDA 
Form 1572  
• Copy of the IRB /IEC  approval letter for the study and approved VICF  
• IRB/IEC  Membership List  
 
Additional country specific documentation may be required per international regulatory 
authorities. Docume nts will be collected by the CRO  per regulatory requirements.  
10.2 Investigator Obligations  
The PI is responsible for ensuring that all study site personnel, including subinvestigators and 
other study staff members, adhere to all FDA regulations and guidelines regarding clinical 
trials, including guidelines for GCP (including the archiving of essential documents), both 
during and after study completion. The PI will be responsible for the patient ’s compliance to 
the study protoco l. The PI is responsible for providing the sponsor an adequate final report 
shortly after he/she completes participation in the study, in accordance with ICH Guidelines 
E6, E2A, and E8 . 
10.3 Patien t Confidentiality  
All information obtained during the conduct of the st udy with respect to the patients ’ state of 
health will be regarded as confidential . This is detailed in the written information provided to 
the patient . An agreement for disclosure of any such information will be obtained in writing 
and is included in both  copies of the VICF signed by the patient . The study data shall not be 
disclosed to a third party without the written consent of the sponsor .   
10.4 Informed Consent  
According to the ICH guideline for GCP (E6), the investigator will obtain and document 
informed  consent for each patient  screened for this study. All patient s will be informed in 
writing of the nature of the protocol and investigational therapy, its possible hazards, and 
their right to withdraw at any time, and will sign a form indicating their cons ent to participate 
prior to the initiation of study procedures. The patien t’s medical record should contain 
written documentation indicating that  informed consent was obtained.  The VICF must be 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 82 of 101 reviewed and approved by the investigator’s designated IRB /IEC  and by the sponsor . The 
VICF should include all the elements as outlined in Section 4.8.10 of the ICH guideline for 
GCP (E6).  
10.5 Institutional Review Board  
This protocol and relevant supporting data are to be submitted to the appropriate IRB /IEC  for 
review a nd approval befo re the study can be initiated. Amendments to the protocol will also 
be submitted to the IRB /IEC  prior t o implementation of the change.  The sponsor must 
receive a letter documenting the IRB /IEC  approval pri or to initiation of the study. The PI is 
also responsible for informing the IRB /IEC  of the progress of the study and for  obtaining 
annual IRB /IEC  renewal. The IRB must be informed at the time of completion of the study 
and should be provided with a summary of the  results of the study by the  PI. The PI must 
notify the IRB /IEC  in writing of any SAE or any unexpected AE according to ICH 
guidelines.  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 83 of 101 11 PROTOCOL MANAGEMENT AND ADMINISTRATIVE 
CONSIDERATIONS  
11.1 Study Documentation  
The PI and study staff has the responsibility of maintaining a comprehensi ve and centralized 
filing system containing al l study -related documentation. These files must be available for 
inspection by the sponsor , representatives of the sponsor , the IRB /IEC , and regulatory 
authorities (i.e., FDA or international regulatory authori ties) at any time, and should consist 
of the following elements:  
Patient  files, containing the completed case report forms (CRFs), supporting source 
documentation from the medical record including laboratory data and the VICF;  
Regulatory files, containing the protocol with all amendments and investigator signature 
pages, copies of all other regulatory documentation, and all correspondence between the site 
and the IRB /IEC  and sponsor ; and Drug accountability files, including a complete account of 
the receipt  and disposition of the study medication (test article).  
Records are to be available for 2 years after marketing application approval, or if the 
application is not approved or never submitted, 2 years after the last shipment and delivery of 
the material an d the appropriate competent regula tory authorities are notified. The sponsor 
will provide written notification when it is appropriate for the investigator(s) to discard the 
study -specific documents referenced above.  
11.2 Protocol Interpretation and Compliance  
To ensure accurate interpretation and implementation of the study, the procedures and 
endpoints defined in the protocol will be carefully reviewed by the PI and his or her staff 
prior t o the time of study initiation. The sponsor and PI will follow all reaso nable means to 
resolve any differences of opinion of matters of eligibility, toxicity and other endpoints.  In 
the event that a resolution cannot be reached then one or both parties may seek to terminate 
the study following the provisions outlined in the C linical Trials Agreement.  
11.3 Study Monitoring  
The sponsor or a contracted monitor will visit the study center periodically to monitor 
adherence to the protocol, compliance with ICH guidelines, adherence to applicable FDA 
regulations, and the maintenance of ad equate and accurate clinical records.  Case report 
forms will be reviewed to ensure that key safety and efficacy data are collected and recorde d 
as specified by the protocol.  The monitor will be permitted to access patient s’ complete 
medical records, labor atory data, and other source documentation as needed to monitor the 
trial appropriately.  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 84 of 101 12 PRINCIPAL INVESTIGAT OR SIGNATURE PAGE  
I agree to conduct the study as outlined in the protocol entitled, “ A Phase 2, Randomized, 
Double -Blind, Placebo -Controlled, Parallel Group, Multi -Center Study to Investigate the 
Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative 
Colitis ” in accordance with the guidelines and all applicable government regu lations 
including Part 54: Financial Disclos ure by Clinical Investigators. These guidelines and 
regulations include, but are not limited to:  
• Permission to allow the sponsor, or designee, and the FDA or other country specific 
regulatory agencies to inspect study facilities and pertinent records at reasonable times 
and in a reasonable manner that ensures patient  confidentiality. If this study is to be 
inspected by a regulatory agency, the sponsor and CRO should be notified as soon as 
possible.  
• Submission of t he proposed clinical investigation, including the protocol and the 
consent form, to a duly constituted IRB /IEC  for approval, and acquisition of written 
approval for each prior to the use of the study drug.  
• Use of written informed consent that is obtained prior to administration of study drug 
or any non -routine procedures that involve risk, and that contains all the elements of 
consent as specified in the federal regulations and has been previously approved by the 
sponsor and the IRB /IEC . 
• Submission of any proposed change in the protocol to the IRB /IEC  using a signed 
formal amendment document approved by the sponsor. Any proposed changes to the 
protocol require that the informed consent also reflect such changes and that the revised 
informed consent be appro ved as determined by the IRB /IEC .  
• Documentation and explanation of individual protocol deviations.  
• Submission of SAE reports within 24 hours after the investigator’s initial receipt of the 
information.  
• If required by local regulation , submission of report s of SAEs, as outlined in the 
protocol, to the IRB /IEC  within 15 calendar days of their disclosure.  
• Submission of timely progress reports to the IRB /IEC  and sponsor at appropriate 
intervals on a schedule determined by the IRB /IEC .  
• Maintenance of appropria te records: Federal regulations require an investigator to 
prepare and maintain adequate and accurate case histories designed to record all 
observations and other data (such as study drug accountability) pertinent to the 
investigation on each ind ividual en rolled in the study.  These records must be 
maintained by the investigator until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or a t least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product.  
 
In addition, I agree to provide all the information requested in the CRF in a manner to a ssure 
legibility and accuracy. To this end, I s hall carefully follow the instructions for completing 
CRFs.  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 85 of 101 I also agree that all information provided to me by the sponsor, including protocols, CRFs, 
and verbal and written information, will be kept strictly confidential and confined to the 
clinical pers onnel involved in conducting the study.  It is recognized that this information 
may be related in confidence to the IRB /IEC .  I also understand that reports of information 
about the study or its progress will not be provided to anyone not involved in the s tudy other 
than to the PI, or in confidence to the IRB /IEC  or to the FDA or other legally constituted 
authority.  
 
 
Principal Investigator    Date  
 
Printed Name  
 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 86 of 101 13 REFERENCES  
1. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and 
development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov  2010 
November;9(11):883 -97. 
2. Centers for Disease Control and Prevention. Inflammatory bowel disease (IB D). 
http://www.cdc.gov/ibd/ .  Accessed January 8, 2015.  
3. Danese S and Fiocchi C. Ulcerative Colitis. N Engl J Med.  2011  Nov; 365;18 :1713 -1725. 
4. IBD Insights. IBD etiology and pathophysiology: Understanding the process.  
https://www.ibdinsights.com/about/etiology -pathophysiology/ . Accessed January 8, 
2015.  
5. Gasparetto  M and Guariso  G. Highlights in IBD Epidemiology and Its Natural History in 
the Paediatric Age . Gastroenterology Research and Practice, Volume 2013 (2013), 
Article ID 829040, 12 pages.  
6. Crohn’s and Colitis Foundation of America. The Facts About  Inflammatory Bowel 
Diseases. November 2014,  New York, NY 10017.  
http://www.ccfa.org/assets/pdfs/ibdfactbook.pdf . Accessed January 7, 2015.  
7. Loftus EV, Jr. Clinical epidemiology of inflammato ry bowel disease: Incide nce, 
prevalence, and environmental influences. Gastroenterology . 2004; 126:1504 -17. 
8. Burisch J , Jess T , Martinato M , Lakatos PL ; ECCO -EpiCom . The burden of 
inflammatory bowel disease in Eu rope.  J Crohns Colitis.  2013 May;7(4):322 -37. 
9. World IBD Day. http://www.worldibdday.org/index.html . Access ed January  7, 2015.  
10. American Gastroenterological Association. Inflammatory bowel disease eme rges as a 
global disease.  (2012, January 5) . ScienceDaily . 
www.sciencedaily.com/releases/2012/01/120104135402.htm. Accessed January 7, 2015 . 
11. Kaser A , Zeissig S , Blumberg RS . Inflammatory Bowel Disease. Annu Rev Immunol.  
2010;28:573 -621.  
12. Kornbluth  A, Sachar D, MACG and The Practice Parameters Committee of the 
American College of Gastroenterology. Ulcerative Colitis Practice Guidelines in Adults: 
American College of  Gastroenterology, Practice Parameters Committee. Am J 
Gastroenterol  2010; 105:501 –523; doi: 10.1038/ajg.2009.727; published online 12 
January 2010.  
13. Lichtenstein GR, Hanauer SB, Sandborn WJ, and The Practice Parameters Committee of 
the American College of Gastr oenterology. Management of Crohn’s  Disease in Adults . 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 87 of 101 Am J Gastroenterol advance online publication, 6 January 2009; doi: 
10.1038/ajg.2008.168 . 
14. Medscape. Inflammatory Bowel Disease: Practice Essentials.  
http://emedicine.medscape.com/article/179037 -overview#aw2aab6b2b4 . Accessed 
January 8, 2015.  
15. World Health Organization Atlas, “Multiple Sclerosis Resources in the World,” 2008.  
16. Lutton JD, Winston R, Rodman TC. Multi ple sclerosis: etiological mechanisms and 
future directions. Exp Biol Med (Maywood)  2004 January;229(1):12 -20. 
17. Wipfler P, Harrer A, Pilz G, et al. Recent developments in approved and oral multiple 
sclerosis treatment and an update on future treatment options. Drug Discov. Today  2011 
January; 16: 8 -21. 
22. Gergely P , Nuesslein -Hildesheim B, Guerini D et al. The selective sphingosine 1 -
phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species -
specific effects on heart rate. Br J Pharmacol  2012 Nov;167(5):1035 -1047.  
23. Brossard P, Derendorf H, Xu J et al. Pharmacokinetics and pharmacodynamics of 
ponesimod, a selective S1P(1) receptor modulator, in the first -in-human study. Br J Clin 
Pharmacol  2013 Apr 18. doi:10.1111/bcp.12129. [Epub ahead of print] PubMed PMID: 
23594176.  
24. Kovarik JM, Schmouder R , Barilla D et al. Multiple -dose FTY720: tolerability, 
pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol  2004 
May;44(5):532 -537. 
25. http://www.fda.gov/drugs/drugsafe ty/ucm366529.htm . Accessed 27 -April -2015.  
26. Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Publish Date: June 
14, 2010. Accessed October 2010. 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 88 of 101 27. Rutgeerts  P, Sandborn WJ, Feagan BG et al. I nfliximab  for induction  and maintenance  
therapy for ulcerative colitis.  N Engl J Med. 2005 Dec 8;353(23):2462 -2476. 
28. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5 -aminosalicylic acid therapy for 
mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med . 
1987;317:1625 -1629. 
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 89 of 101 PROTOCOL SIGNATURE P AGE  
Protocol Title : A Phase 2, Randomized, Double -Blind, Placebo -Controlled, Parallel Group, 
Multi -Center Study to Investigate the Safety and Efficacy of APD334 in Patients with 
Moderately to Severely Active Ulcerative Colitis  
This study will be conducted in accordance with the International Conference on 
Harmonization (ICH) guideline for Good Clinical Practice (GCP) (E6)  and applicable Food 
and Drug Administration (FDA) guidelines.  
Protocol Number:  APD334 -003 
Arena Pharmaceu ticals, Inc. Signatures:  
 
  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 90 of 101 Appendix 1  Progressive Multifocal Leukoencephalopathy (PML) 
Checklist  
Symptoms “Compared to how you 
usually feel, have you had a 
significant change in any of 
the following?”  If the answer is 
“yes”, obtain a 
description of the 
symptom(s) with 
examples. Applicable Objective 
Test(s): Document 
results on PML 
Object Checklist 
 Yes No   
1) Have you been experiencing 
any persistent difficulty with your vision such as loss of 
vision or double vision? Have 
you been having trouble 
reading?    Test visual fields and 
ocular motility 
2) Have you been experiencing 
any persistent difficulty speaking or having your speech understood by others?    Casual observation of 
speech output for 
dysarthria or aphasia. Ask patient to name a few objects and repeat a multipart phrase. 
3) Have you been experiencing 
any persistent weakness in an 
arm or leg?    Test for pronator draft 
(Barre maneuver) 
and/or fixation on arm 
roll, Assess the ability to hop on either foot; 
foot and finger 
tapping. Test muscle strength. 
4) Have you noticed yourself 
regularly bumping into things or having difficulty writing?    Ask for spontaneous 
writing sample and observe finger to nose, heel to shin, and tandem gait. 
5) Have you regularly been 
experiencing difficulty understanding others?    Ability to follow serial 
commands 
6) Have you had persistent 
problems with your memory or 
thinking?    Recall of 3 objects 
over 1 minute to 
distraction; ability to 
follow commands. 
7) Have you been experiencing 
any persistent numbness or other loss of sensation?    Test sensation side to 
side with pinprock. 
 
  
APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
Confidential  Page 91 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 92 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 93 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 94 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 95 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 96 of 101   

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 97 of 101  
 
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 98 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 99 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 100 of 101  
  

APD334   Arena Pharmaceut icals, Inc.  
Clinical Trial Protocol: APD334 -003 Amendment 06  27 March 2017  
 
 
Confidential  Page 101 of 101 Appendix 3  Mayo Clinic Score – SAMPLE  
Mayo Scoring System for Assessment of Ulcerative Colitis Activity27,* 
Stool Frequency † 
0 = Normal  number  of stools for this patient  
1 = 1 –2 stools more than  normal  
2 = 3 –4 stools more than  normal  
3 = 5 or more stools  more than normal  
Subscore, 0 to 3  
Rectal bleeding ‡ 
0 = No blood seen  
1 = Streaks of blood with stool less than half the time  
2 = Obvious blood with stool most of the time  
3 = Blood alone  passes  
Subscore, 0 to 3  
Findings on  endoscopy†  
0 = Normal or inactive disease  
1 = Mild disease (erythema, decreased vascular pattern ) 
2 = Moderate disease (marked erythema, lack of  vascular pattern, friability, erosions)  
3 = Severe disease (spontaneous bleeding, ulceration)  
Subscore, 0 to 3  
Physician ’s Global Assessment§  
0 = Normal  
1 = Mild  disease  
2 = Moderate  disease  
3 = Severe  disease  
Subscore, 0 to 3  
 
* The Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.28 
† Each patient serves as his or her own control to establish the degree of abnormality of the stool 
frequency.  
† The daily bleeding score represents the most severe bleeding of the day.  
§ The physician’s global assessment acknowledges the three other criteria, the patient’s daily 
recollection of abdominal discomfort and general sense of well -being, and other observati ons, such 
as physical findings and the patient’s performance status . 
 
 
 
This is a representation of an electronic re cord that was signed electronically, and this 
page is the manifestation of the electronic signature. 
 
UserName:  
Title:   
Date: Monday, 03 April 2017, 10:36 AM   Pacific Daylight Time 
Meaning: Author Approval ================================================
UserName:  
Title:    
Date: Monday, 03 April 2017, 12:39 PM   Pacific Daylight Time 
Meaning: Approval ================================================
UserName:  
Title:   
Date: Monday, 03 April 2017, 01:05 PM   Pacific Daylight Time 
Meaning: Approval ================================================
UserName:  
Title:   
Date: Monday, 03 April 2017, 01:07 PM   Pacific Daylight Time 
Meaning: Approval ================================================
UserName:  
Title:   
Date: Monday, 03 April 2017, 01:10 PM   Pacific Daylight Time 
Meaning: Approval ================================================

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 05 10 October 2016
Confidential Page 2of 97PROTOCOL A MENDMENT SUM MARY
The following is a list of major changes made to the APD334 -003 Protocol Amendment 04
dated 21 September 2015. Minor clarifications and corrections have been made throughout 
for consistency . These changes are incorporated in Protocol Amendment 05 dated 10 October 
2016.
Section(s) Amended Page No(s). Description of Changes Made
Header/Footer, Title Page, and 
TOCAllAdded “Amendment 05”, updated date to 
reflect finalization of amended protocol, 
updated pagination and TOC.
Title Page 1 Removed “Sponsor Contact”
Protocol Amendment Summary 2-5Updated table to include summary  of 
changes to the protocol.
Synopsis 11Updated sponsor contact and medical 
monitor.
Synopsis 13, 15Study  Design:
Changed patients with the option 
to enroll in the APD334-005 
extension study : “all patients 
(responders and non -responders)”, 
to: 
Current “responder patients ”

3.1 Overall Study  Design and 
Plan29Reviewed extension study : “A 40 -week 
extension study  (APD3 34-005) is offered 
to all patients (responders and non-
responders)”, to:
Current “A 34-week extension study  
(APD3 34-005) is offered to responder
patients”.
30-32•

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 05 10 October 2016
Confidential Page 3of 97Section(s) Amended Page No(s). Description of Changes Made
•
•
•
•
  
4.2 Inclusion Criteria #6 33 
 
 
4.3Exclusion Criteria, #7 36Revised exclusion of patients that, w ithin 
60 day s prior to randomization, received 
treatment with more than 2 biologic agents 

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 05 10 October 2016
Confidential Page 4of 97Section(s) Amended Page No(s). Description of Changes Made
Current exclusion of patients that, w ithin 
60 day s prior to randomization, received
treatment with more than 3 biologics
5.6Dosage and Administration 40Changed “ Patients will be observed at the 
clinic site for 8 hours post -dose on Day  
1”, to:
Current Patients will be observed at the 
clinic site for 6 hours post -dose on Day  1
5.8.3 Maintenance of 
Randomization Codes and Code-
break Procedures41Added specification that APD334 -003 
study  will remain blinded until completion 
of the APD334- 005 study .
6.4 Vital Signs 44Updated to highlight need for extended 
monitoring if heart rate at 6 hours is the 
lowest since the first dose was 
administered.
6.8.1 Laboratory  Parameters 47Added the following procedure 
information :
clinical safet y laboratory  tests should 
be completed pre -dose 
Complete blood count (CBC) wi ll be 
obtained prior to dosing.
6.9.1 Flexible 
Proctosigmoidoscop y48Revised assessment window from “will be 
performed during screening (within 7 day s 
prior to the administration of the first dose 
of study  drug) ” to
Current: “will be perf ormed during 
screening (within 10 days prior to the 
administration of the first dose of study  
drug) ”.
6.9.7 Complete May o Clinic 
Score, 3-component Mayo Clinic 
Score, and 50Revised MCS from “using … flexible 
proctosigmoidoscop y results within 7 day s 
prior to randomization” to
Current : “within 10 days prior to 
randomization”.

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 05 10 October 2016
Confidential Page 5of 97Section(s) Amended Page No(s). Description of Changes Made
 51
 
6.11.2 Serious Adverse Events 
and Expedited Reporting of 
Adverse Events54, 55Changed recipient of notification of 
serious adverse event from sponsor to 
PPD
6.14 Allowable Visit and 
Procedure Windows59, 60Added possibility  to prolong time window 
for screening to 35 day s. Extended 
window for specified procedures 
(proctosigmoidoscopy ) to 10 day s. 
Removed all other visit and procedure 
windows.
7.1  62Extended window for specified procedures 
to  day s. Added possibility  to prolong 
time window for screening to  day s.
7.2.1 Re-screening 62Added c larification of re -screening 
procedures.
7.4.1 63Changed “ Safety  ECG (12 -lead) pre-dose 
and hourl y through hours post -dose”, to:
Current “Safety  ECG (12- lead) pre-dose 
and hourl y through hours post -dose”
7.4.3  64 
7.4.4Week 12/Exit or Early  
Termination Procedures65Changed “ Determine responder/non-
responder status of p atient for treatment 
assignment in extension study  (APD334 -
005)”, to:
Current “Determine clinical 
responder/non- responder status of p atient 
based on the following criteria…”.

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 04 21 September 2015
ConfidentialPROTOCOL A MENDMENT SUM MARY
The following is a list of major changes made to the APD334 -003 Protocol Amendment 03 
dated 30 June 2015. Minor clarifications and corrections have been made throughout for 
consistency . These changes are incorporated in Protocol Amendment 04 dated 21September
2015.
Section(s) Amended Page No(s). Description of Changes Made
Header/Footer, Title Page, and 
TOCAllAdded “Amendment 04”, updated date to 
reflect finalization of amended protocol, 
updated pagination and TOC.
Protocol Amendment Summary 2-3Updated table to include summary  of 
changes to the protocol.
Synopsis 9 Updated medical monitor for the stud y.
 28-30•
•
4.2 Inclusion Criteria , #10b
6.12.1 Permitted Medications for 
the Treatment of UC33, 55 
 
 
 
  
4.3Exclusion Criteria 35 
 
 
Page 2 of 97

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 04 21 September 2015
ConfidentialSection(s) Amended Page No(s). Description of Changes Made
 
6.3.1 Phy sical Examination 41Revised section to denote that an 
ophthalmoscopy  would be performed as 
part of the ph ysical examination at 
visits and that 
retinal photos will be taken during each 
ophthalmoscopy .
Table 2. Examples of eDiary  
Subscore Entries for Study  
Eligibility  and Corresponding 
Subscore Derivation47 Minor corrections to example table.
7.1  
and
7.4.4  58, 61Added retinal photos to 
physical/neurological examination section.
Page 3 of 97

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 03 30 June 2015
ConfidentialPROTOCOL A MENDMENT SUM MARY
The following is a list of major changes made to the APD334 -003 Protocol Amendment 02
dated 17 June 2015. Minor clarifications and corrections have been made throughout for 
consistency . These changes are incorporated in Protocol Amendment 03 dated 30 June 2015.
Section(s) Amended Page No(s). Description of Changes Made
Header/Footer, Title Page, and 
TOCAllAdded “Amendment 03”, updated date to 
reflect finalization of amended protocol, 
updated pagination and TOC.
Protocol Amendment Summary 2Updated table to include summary  of 
changes to the protocol.
Section 4.3 Exclusion Criteria 33
Section 6.9.1 Flexible 
Proctosigmoidoscop y45The following provision is added to this 
section:
“A repeat flexible 
proctosigmoidoscop y may be 
permitted by  the sponsor when the 
central reader indicates that the 
videoendoscope data was acquired 
incorrectly , or did not meet the 
minimal required quality  standards."
Page 2 of 96

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 02 17 June 2015
ConfidentialPROTOCOL A MENDMENT SUM MARY
The following is a list of major changes made to the APD334 -003 Protocol Amendment 01 
dated 01 May 2015. Minor clarifications and corrections have been made throughout for 
consistency . These changes are incorporated in Protocol Amendment 02 dated 17June 2015.
Section(s) Amended Page No(s). Description of Changes Made
Header/Footer, Title Page, and 
TOCAllAdded “Amendment 02”, updated date to 
reflect finalization of amended protocol, 
updated pagination and TOC.
Title page 1 Updated medical monitor for study .
Protocol Amendment Summary 2-4Updated table to include summary  of 
changes to the original protocol.
Synopsis
Section 9.1.1.4 Exploratory  
Objective(s)
Section 9.5 Efficacy  Endpoints 11, 13-14, 
63-64
Synopsis
Section 9.6.1 Primary  Efficacy  
analysis14, 67Added the following secondary  anal ysis:
•a logistic regression analysis with 
terms for treatment, presence or 
absence of current oral corticosteroid 
therap y at baseline and previous 
exposure to TNFα antagonists and the 
interaction between the 2 stratification 
factors (if appropriate) 
Page 2 of 96

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 02 17 June 2015
ConfidentialSection(s) Amended Page No(s). Description of Changes Made
 
Section 7.1  
Section 7.4.4  29, 59 and 
61 
 
 
30
Section 4.2 I nclusion Criteria #8 32
Section 4.3 Exclusion Criteria 
#27
Section 6.8.1 L aboratory  
Parameters
Section 6.8.2 Virology35, 44-45
 
Section 4.3 Exclusion Criteria 36 
 
Section 5.6 Dosage and 
Administration38Added the following clarification: 
On day s with scheduled study  visits, 
patients should nottake their dose of 
study  medication at home in order to 
complete pre -dose study  procedures.  
Patients must be fasting on the day s of 
their scheduled stud y visits.
Section 6.9.7 Complete May o 
Clinic Score, 3 -component May o 
Clinic Score, and  47, 67Clarified the rounding procedure for the 
primary  endpoint.
Page 3 of 96

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 02 17 June 2015
ConfidentialSection(s) Amended Page No(s). Description of Changes Made
Section 9.6.1 Primary  Efficacy  
Analy sis 
Section 6.12.2 Excluded 
Medications55Added moderate to strong inhibitors of 
CYP2C9 to the excluded medications 
section.
Section 9.6.1.1 Secondary and 
Exploratory  Efficacy  Analy ses68Updated the various analy ses to be 
performed b y ANCOVA.
Section 9.6.2 Subgroup Analy ses 68
Page 4 of 96

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 01 01 May 2015
ConfidentialPROTOCOL A MENDMENT SUM MARY
The following is a list of major changes made to the APD 334-003 Protocol dated 08 April 
2015. Minor clarifications and corrections have been made throughout for consistency . These 
changes are incorporated in Protocol Amendment 01 dated 30 April 2015.
Section(s) Amended Page No(s). Description of Changes Made
Header/Footer, Title Page, and 
TOCAllAdded “Amendment 0 1”,updated date to 
reflect finalization of amended protocol, 
updated pagination and TOC.
Title page 1 Updated medical monitor for study .
Protocol Amendment Summary 2-3Updated table to include summary  of 
changes to the original protocol.
Throughout --Changed the term Partial May o Clinic 
score to 3- component May oClinic score .
Synopsis, 
List of A bbreviations, 
Study  Definition, 
 
 
7 Study  Activities, 
9.1.1.4 Exploratory  Objectives, 
9.5 Efficacy  Endpoints, 
9.6.1.1 Secondary  and 
Exploratory  Endpoints, 11, 13, 17, 
29, 44, 55, 
58, 61, 64, 
65, 82-
92 
Study  Definitions 19 Added definition of intolerable AE
1 Introduction 20 Minor changes to text for clarification
1.2 Ethics and Regulatory  
Considerations, 
Protocol Signature Page24, 80Removed reference to Declaration of 
Helsinki
 27-29•
•
Page 2 of 95

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 01 01 May 2015
ConfidentialSection(s) Amended Page No(s). Description of Changes Made
•
 
 
7.4.4 Week 12/Exit or Early  
Termination Procedures27, 58•  
 
 
 
5.6 Dosage and Administration27, 36-37 
 
4.2 Inclusion Criteria ,
6.12.1 Permitted Medications for 
the Treatment of UC32, 53 
 
4.2 Inclusion Criteria 31-32 
4.3 Exclusion Criteria 33-35Removed separate exclusion criteria 
categories .
5.8.1 Randomization 37Added statement capping the number of 
patients with previous exposure to TNFα 
antagonists 
5.8.2 Blinding , 
6.8.1 L aboratory  Parameters, 
6.11.1 Adverse Event Reporting37, 42, 48Added blinding of  and 
White Blood Cell (WBC) counts from 
sponsor, patients and personnel involved 
in the conduct of the study . These values 
will not be sent to the sites, but reviewed 
by an unblinded CRO phy sician(s) for 
safet y purposes.
Page 3 of 95

APD334 Arena Pharmaceuticals, Inc.
Clinical Trial Protocol: APD334 -003Amendment 01 01 May 2015
ConfidentialSection(s) Amended Page No(s). Description of Changes Made
6.8.1 L aboratory  Parameters 42Added (% and total MB) to creatinine 
kinase and MB subty pe.
6.8.1 L aboratory  Parameters ,
7.1 Screening Visit42, 56 Removed thy roid function tests.
6.8.3 Drugs of Abuse Screen ,
7.4.1 Week 0/Day  1 Procedures43, 57 Removed alcohol (breathaly zer).
6.8.4 Urinal ysis 43Added the following detail to section: 
“Microscopic urinal ysis will be performed 
when there is a positive or abnormal 
macroscopic urinal ysis result” .
6.10  and 
Hematologic Assessments46-47Replaced pharmacod ynamic with 
“hematologic”
6.14 Allowable Visit and 
Procedure Windows54Revised window for 2- week follow -up 
visit to ± 3 day s from last dose
7.4.1 Week 0/Day  1 Procedures, 
7.4.4 Week 12/Exit or Early  
Termination Procedures57, 58Corrected list of laboratory  tests to be 
administered to include hematology .
9.6.2 Subgroup Analy ses 66 
Page 4 of 95
